{
  "vaccines": [
    {
      "id": "hepb_recombivax",
      "name": "Recombivax HB",
      "type": "HepB",
      "manufacturer": "Merck",
      "description": "Hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus. Approved for all ages. 3-dose series (0.5 mL for children 0-19 years) given at 0, 1, and 6 months.",
      "sources": [
        "hepb_recombivax_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One referenced study (Beasley et al., 1983) was a 'Randomized Double-Blind, Placebo-Controlled Trial' for HBIG efficacy. However, the primary vaccine efficacy study in neonates (Section 14.1) used 'untreated historical controls' rather than a concurrent placebo group. The adolescent regimen comparison (Section 14.3) was an 'open, randomized, multicenter study' without placebo control.",
            "level_description": "While one referenced study used placebo control (for HBIG), the main vaccine efficacy data relied on historical controls rather than concurrent placebo groups. Immunogenicity studies were open-label without placebo comparators."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "One referenced study (Beasley et al., 1983) was described as 'Double-Blind.' However, the key adolescent comparison study (Section 14.3) is explicitly described as 'an open, randomized, multicenter study.' Other immunogenicity studies do not specify blinding.",
            "level_description": "Double-blinding was used in one referenced HBIG study but not in the primary vaccine trials. The adolescent regimen comparison was explicitly open-label, which introduces potential observer and participant bias."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The adolescent two-dose vs. three-dose study (Section 14.3) was described as 'an open, randomized, multicenter study.' One referenced study (Beasley et al., 1983) was also randomized. However, no details on randomization methods are provided.",
            "level_description": "Randomization was used in at least one key study and one referenced trial, but no description of randomization methodology (e.g., allocation concealment, sequence generation) is provided in the document."
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.1: '434 doses of RECOMBIVAX HB, 5 mcg, were administered to 147 healthy infants and children (up to 10 years of age).' Section 14.1: '130 infants after nine months of follow-up.' Section 14.2: 'protective level of antibody in 100% of 92 infants, 99% of 129 children, and in 99% of 112 adolescents.' Section 14.3: 255 adolescents in two-dose arm, 121 in three-dose arm.",
            "level_description": "Pediatric sample sizes ranged from 92 to 255 subjects per age group. While adequate for immunogenicity assessment, these are relatively modest sample sizes for detecting rare adverse events. The safety monitoring study (147 children for 434 doses) is small."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Section 6.1: 'monitored for 5 days after each dose.' Section 14.1: 'after nine months of follow-up.' Section 2.4: 'The duration of the protective effect of RECOMBIVAX HB in healthy vaccinees is unknown at present.'",
            "level_description": "Active safety monitoring was limited to only 5 days post-dose, which is inadequate for detecting delayed adverse events. The 9-month efficacy follow-up in neonates is reasonable for infection prevention but inadequate for long-term safety assessment. The document explicitly acknowledges that long-term protective duration is unknown."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Clinical studies reported results separately for: infants and children up to 10 years of age (Section 6.1, 14.2); neonates born to HBsAg/HBeAg positive mothers (Section 14.1); adolescents 11-15 years (Section 14.3); young adults 20-29 years, adults 30-39 years, and adults >=40 years (Section 14.4); predialysis/dialysis patients (Section 14.5).",
            "level_description": "The document provides separate immunogenicity and safety data for multiple age groups including infants, children, adolescents, and adult age brackets, allowing assessment of age-specific responses."
          },
          "inclusion_exclusion_criteria": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Studies included 'healthy infants and children' and 'healthy adults.' Section 14.1 specified neonates 'born of mothers positive for both HBsAg and HBeAg.' Section 14.5 addresses chronic HCV patients and dialysis patients. No detailed inclusion/exclusion criteria are provided.",
            "level_description": "The document describes study populations in general terms (e.g., 'healthy') but does not provide specific inclusion/exclusion criteria, making it impossible to assess the rigor of participant selection or generalizability."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.1 reports adverse reactions by system organ class (General Disorders, Gastrointestinal, Respiratory, Nervous System, Skin, Musculoskeletal, etc.) with frequency thresholds (>1% vs <1%). Specific reactions are listed including injection site reactions, fever (defined as >=101F or >=100F), and systemic complaints.",
            "level_description": "Adverse events are reported by system organ class with frequency categories, suggesting some standardization. However, the document does not describe the use of standardized grading scales or definitions for severity assessment."
          },
          "active_monitoring_serious": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Section 6.1: 'monitored for 5 days after each dose.' Section 6.2 (Post-Marketing Experience) lists serious events reported voluntarily, including Guillain-Barre syndrome, multiple sclerosis, seizures, Stevens-Johnson syndrome, thrombocytopenia, encephalitis, etc., but states 'it is not possible to reliably estimate their frequency or establish a causal relationship.'",
            "level_description": "Active monitoring was limited to 5 days post-vaccination, which is grossly inadequate for detecting serious adverse events that may have delayed onset. Serious events are only captured through passive post-marketing surveillance with acknowledged limitations in establishing causality and frequency."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 6.2 (Post-Marketing Experience) lists: 'Autoimmune diseases including systemic lupus erythematosus (SLE), lupus-like syndrome, vasculitis, and polyarteritis nodosa.' Neurological: 'Guillain-Barre syndrome; multiple sclerosis; exacerbation of multiple sclerosis; myelitis including transverse myelitis; seizure; febrile seizure; peripheral neuropathy including Bell's Palsy; radiculopathy; encephalitis.' These are passive reports only.",
            "level_description": "Autoimmune and neurological events are documented in post-marketing surveillance, but these were not systematically monitored in clinical trials. The document explicitly states a causal relationship cannot be established for these post-marketing reports."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 5.2-5.3 addresses premature infants and infants <2000g. Section 8.1 reports pregnancy data (26 women in clinical studies, 105 in post-approval reports). Section 8.5 notes geriatric populations showed 'diminished antibody response' in subjects >60 years. Section 14.5 covers chronic HCV patients (~70% seroprotection) and predialysis/dialysis patients (lower response rates).",
            "level_description": "Some vulnerable subgroups are addressed (premature infants, pregnancy, elderly, immunocompromised dialysis patients, HCV patients), but data are limited and often from post-marketing or observational sources rather than controlled trials designed to assess these populations."
          },
          "statistical_analysis": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Results are presented as percentages of seroprotection (e.g., '100% of 92 infants,' '96% of 1213 healthy adults,' '99% of 255 subjects'). Section 14.1 states 'estimated efficacy in prevention of chronic hepatitis B infection was 95%.' No confidence intervals, p-values, or statistical methodology is described.",
            "level_description": "The document reports only point estimates without confidence intervals, p-values, or description of statistical methods. The claim that two-dose regimen 'appears similar' to three-dose regimen lacks formal statistical comparison."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Section 15 provides 9 references to published studies and CDC recommendations. Some numerical data are provided (sample sizes, seroconversion rates). However, individual patient data, complete safety databases, and detailed study protocols are not available in this document.",
            "level_description": "The prescribing information references published studies and provides summary statistics, but detailed raw data, complete safety databases, and full study protocols are not included. Access to underlying data would require retrieval of cited references."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 provides extensive post-marketing experience including hypersensitivity reactions, autoimmune diseases, neurological disorders, and other serious events. Section 17 instructs reporting to VAERS. The document states the vaccine has been marketed since 1986 with ongoing surveillance through 2018 (revision date).",
            "level_description": "The document includes a comprehensive list of post-marketing adverse events and provides mechanisms for ongoing surveillance (VAERS, manufacturer reporting). Over 30 years of post-marketing data collection is reflected."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document identifies Merck Sharp & Dohme Corp. as manufacturer and distributor. No disclosure of conflicts of interest, funding sources for clinical trials, or investigator relationships is provided.",
            "level_description": "The prescribing information does not include any conflict of interest disclosures or information about trial funding. The manufacturer conducted the studies but no financial relationships or potential biases are addressed."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No mortality data or death rates are reported in the clinical trials section or adverse events section. The document does not provide information on all-cause mortality in vaccinated vs. control groups.",
            "level_description": "The document contains no information about deaths in clinical trials or all-cause mortality comparisons. This critical safety endpoint is not addressed."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB prescribing information reflects trials from the 1980s era with methodological limitations by current standards. Strengths include separate age group analysis, adequate immunogenicity data, and extensive post-marketing surveillance over 30+ years. Significant limitations include: reliance on historical rather than concurrent placebo controls for efficacy, open-label design in key trials, very short active safety monitoring (5 days), absence of statistical rigor in reporting (no confidence intervals or p-values), no mortality data, and no conflict of interest disclosure. The document adequately demonstrates immunogenicity but provides limited evidence for comprehensive safety assessment, particularly for rare or delayed adverse events."
        }
      },
      "trial_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um estudo referenciado (Beasley et al., 1983) foi um 'Ensaio Randomizado Duplo-Cego Controlado por Placebo' para efic√°cia de HBIG. No entanto, o estudo prim√°rio de efic√°cia da vacina em neonatos (Se√ß√£o 14.1) utilizou 'controles hist√≥ricos n√£o tratados' em vez de um grupo placebo concorrente. A compara√ß√£o de regime em adolescentes (Se√ß√£o 14.3) foi um 'estudo aberto, randomizado e multic√™ntrico' sem controle placebo.",
            "level_description": "Embora um estudo referenciado tenha usado controle placebo (para HBIG), os principais dados de efic√°cia da vacina basearam-se em controles hist√≥ricos em vez de grupos placebo concorrentes. Os estudos de imunogenicidade foram abertos, sem comparadores placebo."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um estudo referenciado (Beasley et al., 1983) foi descrito como 'Duplo-Cego'. No entanto, o principal estudo comparativo em adolescentes (Se√ß√£o 14.3) √© explicitamente descrito como 'um estudo aberto, randomizado e multic√™ntrico'. Outros estudos de imunogenicidade n√£o especificam o cegamento.",
            "level_description": "O duplo-cegamento foi utilizado em um estudo referenciado de HBIG, mas n√£o nos ensaios prim√°rios da vacina. A compara√ß√£o de regime em adolescentes foi explicitamente aberta, o que introduz potencial vi√©s do observador e do participante."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O estudo de duas doses versus tr√™s doses em adolescentes (Se√ß√£o 14.3) foi descrito como 'um estudo aberto, randomizado e multic√™ntrico'. Um estudo referenciado (Beasley et al., 1983) tamb√©m foi randomizado. No entanto, nenhum detalhe sobre os m√©todos de randomiza√ß√£o √© fornecido.",
            "level_description": "A randomiza√ß√£o foi utilizada em pelo menos um estudo principal e um ensaio referenciado, mas nenhuma descri√ß√£o da metodologia de randomiza√ß√£o (por exemplo, oculta√ß√£o de aloca√ß√£o, gera√ß√£o de sequ√™ncia) √© fornecida no documento."
          },
          "pediatric_sample_size": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Se√ß√£o 6.1: '434 doses de RECOMBIVAX HB, 5 mcg, foram administradas a 147 beb√™s e crian√ßas saud√°veis (at√© 10 anos de idade).' Se√ß√£o 14.1: '130 beb√™s ap√≥s nove meses de acompanhamento.' Se√ß√£o 14.2: 'n√≠vel protetor de anticorpos em 100% de 92 beb√™s, 99% de 129 crian√ßas e em 99% de 112 adolescentes.' Se√ß√£o 14.3: 255 adolescentes no bra√ßo de duas doses, 121 no bra√ßo de tr√™s doses.",
            "level_description": "Os tamanhos de amostra pedi√°trica variaram de 92 a 255 indiv√≠duos por faixa et√°ria. Embora adequados para avalia√ß√£o de imunogenicidade, s√£o tamanhos de amostra relativamente modestos para detectar eventos adversos raros. O estudo de monitoramento de seguran√ßa (147 crian√ßas para 434 doses) √© pequeno."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Se√ß√£o 6.1: 'monitorados por 5 dias ap√≥s cada dose.' Se√ß√£o 14.1: 'ap√≥s nove meses de acompanhamento.' Se√ß√£o 2.4: 'A dura√ß√£o do efeito protetor de RECOMBIVAX HB em vacinados saud√°veis √© desconhecida no momento.'",
            "level_description": "O monitoramento ativo de seguran√ßa foi limitado a apenas 5 dias p√≥s-dose, o que √© inadequado para detectar eventos adversos tardios. O acompanhamento de efic√°cia de 9 meses em neonatos √© razo√°vel para preven√ß√£o de infec√ß√£o, mas inadequado para avalia√ß√£o de seguran√ßa a longo prazo. O documento reconhece explicitamente que a dura√ß√£o da prote√ß√£o a longo prazo √© desconhecida."
          },
          "separate_age_groups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Os estudos cl√≠nicos relataram resultados separadamente para: beb√™s e crian√ßas at√© 10 anos de idade (Se√ß√£o 6.1, 14.2); neonatos nascidos de m√£es positivas para HBsAg/HBeAg (Se√ß√£o 14.1); adolescentes de 11-15 anos (Se√ß√£o 14.3); adultos jovens de 20-29 anos, adultos de 30-39 anos e adultos >=40 anos (Se√ß√£o 14.4); pacientes em pr√©-di√°lise/di√°lise (Se√ß√£o 14.5).",
            "level_description": "O documento fornece dados separados de imunogenicidade e seguran√ßa para m√∫ltiplas faixas et√°rias, incluindo beb√™s, crian√ßas, adolescentes e faixas et√°rias adultas, permitindo avalia√ß√£o de respostas espec√≠ficas por idade."
          },
          "inclusion_exclusion_criteria": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os estudos inclu√≠ram 'beb√™s e crian√ßas saud√°veis' e 'adultos saud√°veis'. A Se√ß√£o 14.1 especificou neonatos 'nascidos de m√£es positivas tanto para HBsAg quanto para HBeAg'. A Se√ß√£o 14.5 aborda pacientes com HCV cr√¥nico e pacientes em di√°lise. Nenhum crit√©rio detalhado de inclus√£o/exclus√£o √© fornecido.",
            "level_description": "O documento descreve as popula√ß√µes do estudo em termos gerais (por exemplo, 'saud√°veis'), mas n√£o fornece crit√©rios espec√≠ficos de inclus√£o/exclus√£o, tornando imposs√≠vel avaliar o rigor da sele√ß√£o de participantes ou a generaliza√ß√£o dos resultados."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.1 relata rea√ß√µes adversas por classe de sistema org√¢nico (Dist√∫rbios Gerais, Gastrointestinais, Respirat√≥rios, Sistema Nervoso, Pele, Musculoesquel√©ticos, etc.) com limites de frequ√™ncia (>1% vs <1%). Rea√ß√µes espec√≠ficas s√£o listadas, incluindo rea√ß√µes no local da inje√ß√£o, febre (definida como >=101F ou >=100F) e queixas sist√™micas.",
            "level_description": "Os eventos adversos s√£o relatados por classe de sistema org√¢nico com categorias de frequ√™ncia, sugerindo alguma padroniza√ß√£o. No entanto, o documento n√£o descreve o uso de escalas padronizadas de gradua√ß√£o ou defini√ß√µes para avalia√ß√£o de gravidade."
          },
          "active_monitoring_serious": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Se√ß√£o 6.1: 'monitorados por 5 dias ap√≥s cada dose.' A Se√ß√£o 6.2 (Experi√™ncia P√≥s-Comercializa√ß√£o) lista eventos graves relatados voluntariamente, incluindo s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla, convuls√µes, s√≠ndrome de Stevens-Johnson, trombocitopenia, encefalite, etc., mas afirma que 'n√£o √© poss√≠vel estimar com confiabilidade sua frequ√™ncia ou estabelecer uma rela√ß√£o causal.'",
            "level_description": "O monitoramento ativo foi limitado a 5 dias p√≥s-vacina√ß√£o, o que √© grosseiramente inadequado para detectar eventos adversos graves que podem ter in√≠cio tardio. Eventos graves s√£o capturados apenas por meio de vigil√¢ncia passiva p√≥s-comercializa√ß√£o com limita√ß√µes reconhecidas no estabelecimento de causalidade e frequ√™ncia."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 6.2 (Experi√™ncia P√≥s-Comercializa√ß√£o) lista: 'Doen√ßas autoimunes incluindo l√∫pus eritematoso sist√™mico (LES), s√≠ndrome tipo l√∫pus, vasculite e poliarterite nodosa.' Neurol√≥gico: 'S√≠ndrome de Guillain-Barr√©; esclerose m√∫ltipla; exacerba√ß√£o de esclerose m√∫ltipla; mielite incluindo mielite transversa; convuls√£o; convuls√£o febril; neuropatia perif√©rica incluindo paralisia de Bell; radiculopatia; encefalite.' Estes s√£o apenas relatos passivos.",
            "level_description": "Eventos autoimunes e neurol√≥gicos s√£o documentados na vigil√¢ncia p√≥s-comercializa√ß√£o, mas n√£o foram monitorados sistematicamente nos ensaios cl√≠nicos. O documento afirma explicitamente que uma rela√ß√£o causal n√£o pode ser estabelecida para esses relatos p√≥s-comercializa√ß√£o."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As Se√ß√µes 5.2-5.3 abordam beb√™s prematuros e beb√™s <2000g. A Se√ß√£o 8.1 relata dados de gravidez (26 mulheres em estudos cl√≠nicos, 105 em relatos p√≥s-aprova√ß√£o). A Se√ß√£o 8.5 observa que popula√ß√µes geri√°tricas apresentaram 'resposta de anticorpos diminu√≠da' em indiv√≠duos >60 anos. A Se√ß√£o 14.5 abrange pacientes com HCV cr√¥nico (~70% de soroprote√ß√£o) e pacientes em pr√©-di√°lise/di√°lise (taxas de resposta mais baixas).",
            "level_description": "Alguns subgrupos vulner√°veis s√£o abordados (beb√™s prematuros, gravidez, idosos, pacientes em di√°lise imunocomprometidos, pacientes com HCV), mas os dados s√£o limitados e frequentemente provenientes de fontes p√≥s-comercializa√ß√£o ou observacionais, em vez de ensaios controlados projetados para avaliar essas popula√ß√µes."
          },
          "statistical_analysis": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os resultados s√£o apresentados como porcentagens de soroprote√ß√£o (por exemplo, '100% de 92 beb√™s', '96% de 1213 adultos saud√°veis', '99% de 255 indiv√≠duos'). A Se√ß√£o 14.1 afirma que 'a efic√°cia estimada na preven√ß√£o de infec√ß√£o cr√¥nica por hepatite B foi de 95%.' Nenhum intervalo de confian√ßa, valores-p ou metodologia estat√≠stica √© descrita.",
            "level_description": "O documento relata apenas estimativas pontuais sem intervalos de confian√ßa, valores-p ou descri√ß√£o de m√©todos estat√≠sticos. A afirma√ß√£o de que o regime de duas doses 'parece similar' ao regime de tr√™s doses carece de compara√ß√£o estat√≠stica formal."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A Se√ß√£o 15 fornece 9 refer√™ncias a estudos publicados e recomenda√ß√µes do CDC. Alguns dados num√©ricos s√£o fornecidos (tamanhos de amostra, taxas de soroconvers√£o). No entanto, dados individuais de pacientes, bancos de dados completos de seguran√ßa e protocolos detalhados dos estudos n√£o est√£o dispon√≠veis neste documento.",
            "level_description": "As informa√ß√µes de prescri√ß√£o fazem refer√™ncia a estudos publicados e fornecem estat√≠sticas resumidas, mas dados brutos detalhados, bancos de dados completos de seguran√ßa e protocolos completos dos estudos n√£o est√£o inclu√≠dos. O acesso aos dados subjacentes exigiria a recupera√ß√£o das refer√™ncias citadas."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 fornece extensa experi√™ncia p√≥s-comercializa√ß√£o, incluindo rea√ß√µes de hipersensibilidade, doen√ßas autoimunes, dist√∫rbios neurol√≥gicos e outros eventos graves. A Se√ß√£o 17 instrui a reportar ao VAERS. O documento afirma que a vacina est√° no mercado desde 1986 com vigil√¢ncia cont√≠nua at√© 2018 (data de revis√£o).",
            "level_description": "O documento inclui uma lista abrangente de eventos adversos p√≥s-comercializa√ß√£o e fornece mecanismos para vigil√¢ncia cont√≠nua (VAERS, relatos ao fabricante). Mais de 30 anos de coleta de dados p√≥s-comercializa√ß√£o est√£o refletidos."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento identifica Merck Sharp & Dohme Corp. como fabricante e distribuidor. Nenhuma divulga√ß√£o de conflitos de interesse, fontes de financiamento para ensaios cl√≠nicos ou relacionamentos de investigadores √© fornecida.",
            "level_description": "As informa√ß√µes de prescri√ß√£o n√£o incluem nenhuma divulga√ß√£o de conflito de interesse ou informa√ß√£o sobre financiamento dos ensaios. O fabricante conduziu os estudos, mas nenhuma rela√ß√£o financeira ou potenciais vieses s√£o abordados."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Nenhum dado de mortalidade ou taxas de √≥bito s√£o relatados na se√ß√£o de ensaios cl√≠nicos ou se√ß√£o de eventos adversos. O documento n√£o fornece informa√ß√µes sobre mortalidade por todas as causas em grupos vacinados versus grupos controle.",
            "level_description": "O documento n√£o cont√©m informa√ß√µes sobre √≥bitos em ensaios cl√≠nicos ou compara√ß√µes de mortalidade por todas as causas. Este desfecho cr√≠tico de seguran√ßa n√£o √© abordado."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "As informa√ß√µes de prescri√ß√£o do RECOMBIVAX HB refletem ensaios da d√©cada de 1980 com limita√ß√µes metodol√≥gicas pelos padr√µes atuais. Os pontos fortes incluem an√°lise separada por faixa et√°ria, dados adequados de imunogenicidade e extensa vigil√¢ncia p√≥s-comercializa√ß√£o por mais de 30 anos. Limita√ß√µes significativas incluem: depend√™ncia de controles hist√≥ricos em vez de controles placebo concorrentes para efic√°cia, desenho aberto em ensaios-chave, monitoramento ativo de seguran√ßa muito curto (5 dias), aus√™ncia de rigor estat√≠stico nos relatos (sem intervalos de confian√ßa ou valores-p), aus√™ncia de dados de mortalidade e nenhuma divulga√ß√£o de conflito de interesse. O documento demonstra adequadamente a imunogenicidade, mas fornece evid√™ncias limitadas para avalia√ß√£o abrangente de seguran√ßa, particularmente para eventos adversos raros ou tardios."
        }
      },
      "safety_en": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The pediatric clinical trial data is limited. Only 147 healthy infants and children (up to 10 years of age) received 434 doses across three clinical studies. For adolescents, the two-dose vs three-dose regimen comparison included 255 and 121 subjects respectively. While safety was established across all pediatric age groups, the sample sizes are relatively small for detecting rare adverse events in a vaccine approved since 1986 and administered to millions of children."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Follow-up was extremely limited. In the pediatric studies, subjects were monitored for only 5 days after each dose. In adult studies, monitoring was similarly limited to 5 days after each dose. For neonates with peripartum exposure, follow-up extended to 9 months, but this was primarily to assess efficacy (prevention of chronic infection) rather than comprehensive safety monitoring. No long-term safety follow-up data is presented in the prescribing information."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document references 'historical controls' for efficacy comparisons in neonates (untreated historical controls and those receiving only HBIG). The adolescent two-dose vs three-dose study was randomized and open-label. However, the document does not describe placebo-controlled trials or true randomized safety comparisons for the primary clinical studies. The comparison methodology for safety assessment is not well documented."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials used active monitoring for 5 days after each dose, capturing injection site reactions and systemic adverse reactions. However, the short duration limits the ability to detect delayed-onset adverse events. The document mentions that adverse reactions were 'monitored' but does not detail the surveillance methodology (e.g., diaries, follow-up calls, clinic visits). Post-marketing surveillance relies on voluntary VAERS reporting rather than active surveillance."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Clinical trials captured some neurological symptoms including vertigo/dizziness and paresthesia at <1% incidence. Post-marketing reports include serious neurological events: Guillain-Barre syndrome, multiple sclerosis and its exacerbation, transverse myelitis, seizures, febrile seizures, peripheral neuropathy (including Bell's Palsy), radiculopathy, encephalitis, optic neuritis, and muscle weakness. However, no systematic neurological monitoring protocol is described in the pre-licensure trials."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The document addresses several vulnerable populations: premature infants (warning about apnea risk), infants weighing <2000g (vaccination delay recommendations), dialysis/predialysis patients (separate formulation and dosing), pregnant women (post-approval data from 26 clinical study pregnancies and 105 post-approval reports showing background-rate outcomes), and elderly (noted diminished antibody response in >60 years). Chronic hepatitis C patients and immunocompromised populations are also discussed regarding immunogenicity."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document provides aggregate adverse reaction rates (e.g., 17% injection site reactions, 15% systemic reactions in adults; 0.2% and 10.4% in children) and lists adverse events by incidence category (>1% vs <1%). However, detailed study designs, statistical analyses, confidence intervals, and raw data tables are not included. Individual study protocols are not described. The document acknowledges that post-marketing events cannot establish causality due to voluntary reporting from uncertain population sizes."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 provides a comprehensive list of post-marketing adverse events organized by system organ class, including serious events like anaphylaxis, autoimmune diseases (SLE, vasculitis, polyarteritis nodosa), neurological disorders, and skin reactions (Stevens-Johnson syndrome). The document references VAERS reporting system with contact information. Post-approval pregnancy data spans 1986-2018 with 105 pregnancies tracked. However, the document notes inability to establish causality or reliable frequency estimates from voluntary reports."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB, approved in 1986, has limited pre-licensure safety documentation by modern standards. Pediatric trials included only 147 children with just 5-day follow-up periods, which is insufficient to detect rare or delayed adverse events. The document lacks placebo-controlled trial data and detailed study methodologies. However, some strengths exist: vulnerable subgroups (premature infants, dialysis patients, pregnant women) are reasonably addressed, and post-marketing surveillance has accumulated decades of data identifying serious but rare events including neurological and autoimmune conditions. The overall safety profile relies heavily on post-marketing experience rather than robust pre-licensure evidence, reflecting the regulatory standards of the 1980s rather than current requirements."
        }
      },
      "safety_pt": {
        "vaccine_id": "hepb_recombivax",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Os dados de ensaios cl√≠nicos pedi√°tricos s√£o limitados. Apenas 147 beb√™s e crian√ßas saud√°veis (at√© 10 anos de idade) receberam 434 doses em tr√™s estudos cl√≠nicos. Para adolescentes, a compara√ß√£o entre o regime de duas doses versus tr√™s doses incluiu 255 e 121 participantes, respectivamente. Embora a seguran√ßa tenha sido estabelecida em todos os grupos et√°rios pedi√°tricos, os tamanhos das amostras s√£o relativamente pequenos para detectar eventos adversos raros em uma vacina aprovada desde 1986 e administrada a milh√µes de crian√ßas."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento foi extremamente limitado. Nos estudos pedi√°tricos, os participantes foram monitorados por apenas 5 dias ap√≥s cada dose. Nos estudos com adultos, o monitoramento foi igualmente limitado a 5 dias ap√≥s cada dose. Para neonatos com exposi√ß√£o periparto, o acompanhamento estendeu-se at√© 9 meses, mas isso foi principalmente para avaliar a efic√°cia (preven√ß√£o de infec√ß√£o cr√¥nica) em vez de monitoramento abrangente de seguran√ßa. Nenhum dado de acompanhamento de seguran√ßa a longo prazo √© apresentado nas informa√ß√µes de prescri√ß√£o."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento faz refer√™ncia a 'controles hist√≥ricos' para compara√ß√µes de efic√°cia em neonatos (controles hist√≥ricos n√£o tratados e aqueles que receberam apenas HBIG). O estudo comparativo de duas doses versus tr√™s doses em adolescentes foi randomizado e aberto. No entanto, o documento n√£o descreve ensaios controlados por placebo ou compara√ß√µes de seguran√ßa verdadeiramente randomizadas para os estudos cl√≠nicos prim√°rios. A metodologia de compara√ß√£o para avalia√ß√£o de seguran√ßa n√£o est√° bem documentada."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os ensaios cl√≠nicos utilizaram monitoramento ativo por 5 dias ap√≥s cada dose, registrando rea√ß√µes no local da inje√ß√£o e rea√ß√µes sist√™micas adversas. No entanto, a curta dura√ß√£o limita a capacidade de detectar eventos adversos de in√≠cio tardio. O documento menciona que as rea√ß√µes adversas foram 'monitoradas', mas n√£o detalha a metodologia de vigil√¢ncia (por exemplo, di√°rios, liga√ß√µes de acompanhamento, visitas cl√≠nicas). A vigil√¢ncia p√≥s-comercializa√ß√£o depende de relatos volunt√°rios ao VAERS em vez de vigil√¢ncia ativa."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Os ensaios cl√≠nicos registraram alguns sintomas neurol√≥gicos, incluindo vertigem/tontura e parestesia com incid√™ncia <1%. Os relatos p√≥s-comercializa√ß√£o incluem eventos neurol√≥gicos graves: s√≠ndrome de Guillain-Barr√©, esclerose m√∫ltipla e sua exacerba√ß√£o, mielite transversa, convuls√µes, convuls√µes febris, neuropatia perif√©rica (incluindo paralisia de Bell), radiculopatia, encefalite, neurite √≥ptica e fraqueza muscular. No entanto, nenhum protocolo sistem√°tico de monitoramento neurol√≥gico √© descrito nos ensaios pr√©-licenciamento."
          },
          "vulnerable_subgroups": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O documento aborda v√°rias popula√ß√µes vulner√°veis: beb√™s prematuros (advert√™ncia sobre risco de apneia), beb√™s com peso <2000g (recomenda√ß√µes de adiamento da vacina√ß√£o), pacientes em di√°lise/pr√©-di√°lise (formula√ß√£o e dosagem separadas), gestantes (dados p√≥s-aprova√ß√£o de 26 gesta√ß√µes em estudos cl√≠nicos e 105 relatos p√≥s-aprova√ß√£o mostrando resultados dentro das taxas basais) e idosos (resposta diminu√≠da de anticorpos observada em >60 anos). Pacientes com hepatite C cr√¥nica e popula√ß√µes imunocomprometidas tamb√©m s√£o discutidos em rela√ß√£o √† imunogenicidade."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento fornece taxas agregadas de rea√ß√µes adversas (por exemplo, 17% de rea√ß√µes no local da inje√ß√£o, 15% de rea√ß√µes sist√™micas em adultos; 0,2% e 10,4% em crian√ßas) e lista eventos adversos por categoria de incid√™ncia (>1% vs <1%). No entanto, desenhos detalhados dos estudos, an√°lises estat√≠sticas, intervalos de confian√ßa e tabelas de dados brutos n√£o est√£o inclu√≠dos. Os protocolos individuais dos estudos n√£o s√£o descritos. O documento reconhece que os eventos p√≥s-comercializa√ß√£o n√£o podem estabelecer causalidade devido a relatos volunt√°rios de tamanhos populacionais incertos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 fornece uma lista abrangente de eventos adversos p√≥s-comercializa√ß√£o organizados por classe de sistema de √≥rg√£os, incluindo eventos graves como anafilaxia, doen√ßas autoimunes (LES, vasculite, poliarterite nodosa), dist√∫rbios neurol√≥gicos e rea√ß√µes cut√¢neas (s√≠ndrome de Stevens-Johnson). O documento faz refer√™ncia ao sistema de notifica√ß√£o VAERS com informa√ß√µes de contato. Os dados de gravidez p√≥s-aprova√ß√£o abrangem 1986-2018 com 105 gesta√ß√µes acompanhadas. No entanto, o documento observa a incapacidade de estabelecer causalidade ou estimativas de frequ√™ncia confi√°veis a partir de relatos volunt√°rios."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "RECOMBIVAX HB, aprovada em 1986, possui documenta√ß√£o de seguran√ßa pr√©-licenciamento limitada pelos padr√µes modernos. Os ensaios pedi√°tricos inclu√≠ram apenas 147 crian√ßas com per√≠odos de acompanhamento de apenas 5 dias, o que √© insuficiente para detectar eventos adversos raros ou tardios. O documento carece de dados de ensaios controlados por placebo e metodologias detalhadas dos estudos. No entanto, existem alguns pontos fortes: subgrupos vulner√°veis (beb√™s prematuros, pacientes em di√°lise, gestantes) s√£o razoavelmente abordados, e a vigil√¢ncia p√≥s-comercializa√ß√£o acumulou d√©cadas de dados identificando eventos graves, por√©m raros, incluindo condi√ß√µes neurol√≥gicas e autoimunes. O perfil geral de seguran√ßa depende fortemente da experi√™ncia p√≥s-comercializa√ß√£o em vez de evid√™ncias pr√©-licenciamento robustas, refletindo os padr√µes regulat√≥rios da d√©cada de 1980 em vez dos requisitos atuais."
        }
      }
    },
    {
      "id": "hib_hiberix",
      "name": "Hiberix",
      "type": "Hib",
      "manufacturer": "GlaxoSmithKline",
      "description": "Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) for prevention of invasive disease caused by H. influenzae type b. Approved for children 6 weeks through 4 years. 4-dose series at 2, 4, 6, and 15-18 months of age.",
      "sources": [
        "hib_hiberix_insert.pdf"
      ],
      "trial_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Study 1 compared HIBERIX (n=2,963) with active comparators: Control PRP-T (Sanofi Pasteur SA) (n=520) and DTaP-IPV/Hib (Sanofi Pasteur Ltd.) (n=520). No inert placebo group was used.",
            "level_description": "The clinical trials used active vaccine comparators rather than saline placebo controls. All comparison groups received other Hib-containing vaccines, making it impossible to assess the true safety profile of HIBERIX against an unvaccinated baseline."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 1 is described as 'randomized, controlled clinical trial' but blinding is not explicitly mentioned. Study 2 is described as 'open-label, multicenter study.'",
            "level_description": "The main U.S. Study 1 appears to be randomized but blinding methodology is not documented. Study 2 and the 7 additional studies were explicitly open-label, meaning investigators and participants knew which vaccine was administered."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 1 is described as 'a randomized, controlled clinical trial conducted in the U.S.' with children randomized to receive HIBERIX (n=2,963), Control PRP-T (n=520), or DTaP-IPV/Hib (n=520).",
            "level_description": "Randomization is explicitly stated for the main U.S. trial (Study 1). However, the randomization methodology, allocation concealment, and stratification details are not provided."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Study 1 enrolled 2,963 children receiving HIBERIX for primary series and 2,336 for booster dose. Seven additional studies included 1,008 children receiving HIBERIX as a booster. Study 2 enrolled 371 children.",
            "level_description": "The total pediatric sample size across studies was substantial (over 4,000 children receiving HIBERIX). The main U.S. trial had nearly 3,000 subjects in the HIBERIX arm, which is adequate for detecting common adverse reactions."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Solicited adverse reactions were collected 'within 4 days of vaccination.' Serious adverse reactions in the 7 additional studies were reported 'in the 31-day period following booster immunization.'",
            "level_description": "Active follow-up for solicited reactions was extremely short at only 4 days post-vaccination. Serious adverse event monitoring extended to 31 days in some studies, but no long-term safety follow-up (months to years) is documented for chronic or delayed adverse effects."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Primary series given at 2, 4, and 6 months. Booster given at 15-18 months. In 7 additional studies, '172 (17.1%) subjects were aged 11 to 14 months, 642 (63.7%) subjects were aged 15 to 18 months, and 194 (19.2%) subjects were aged 19 to 25 months.'",
            "level_description": "Age distribution is documented for booster studies, but separate safety analyses by age subgroup are not presented. Results are aggregated across age groups rather than stratified for comparison."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document mentions contraindications (severe allergic reaction after previous Hib or tetanus toxoid vaccine) and warnings (Guillain-Barre syndrome within 6 weeks, premature infants, immunosuppressed children) but does not detail specific trial inclusion/exclusion criteria.",
            "level_description": "While contraindications and precautions are listed for clinical use, the actual clinical trial eligibility criteria (specific inclusion/exclusion criteria used to screen participants) are not documented in the prescribing information."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Solicited reactions were systematically collected with standardized grading: Grade 3 pain 'cried when limb was moved/spontaneously painful,' Grade 3 irritability 'crying that could not be comforted/prevented normal activity,' Grade 3 fever '>103.1F (>39.5C) rectally.'",
            "level_description": "The trials used standardized definitions and grading scales for solicited adverse events, with clear Grade 3 definitions provided for local and systemic reactions. Diary cards or standardized collection tools appear to have been used."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Serious adverse reactions were reported: 'One of 2,963 subjects...experienced a serious adverse reaction...convulsion on Day 14 after Dose 1.' 'One of 2,336 subjects...experienced...new onset febrile seizure on Day 1 after Dose 4.' In 7 additional studies, '2 of 1,008 subjects reported a serious adverse reaction...in the 31-day period following booster immunization.'",
            "level_description": "Serious adverse events were captured during the trials with temporal associations noted. However, the methodology for active monitoring (frequency of contact, methods of ascertainment) is not described. The 31-day monitoring window is relatively short for detecting serious delayed reactions."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Guillain-Barre syndrome is mentioned as a warning if it occurred within 6 weeks of prior tetanus-containing vaccine. Postmarketing reports include 'Convulsions (with or without fever), hypotonic-hyporesponsive episode (i.e., sudden onset of hypotonia, hyporesponsiveness, and pallor or cyanosis).'",
            "level_description": "Neurological events are addressed in warnings and postmarketing sections, but proactive assessment of autoimmune or neurological outcomes in the clinical trials is not documented. The precaution about Guillain-Barre relates to prior history, not trial monitoring."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Warnings note: 'Safety and effectiveness of HIBERIX in immunosuppressed children have not been evaluated.' 'Apnea following intramuscular vaccination has been observed in some infants born prematurely.'",
            "level_description": "Vulnerable populations such as immunocompromised children and premature infants were explicitly not studied. The document acknowledges these gaps but does not provide safety data for these high-risk subgroups from the clinical trials."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Non-inferiority analyses were performed: 'HIBERIX was non-inferior to Control PRP-T for percent of subjects achieving anti-PRP >=0.15 mcg/mL (lower limit of 95% CI on difference of HIBERIX minus Control PRP-T >= predefined limit of -5%).'",
            "level_description": "Statistical methodology for immunogenicity non-inferiority comparisons is documented with confidence intervals and predefined non-inferiority margins. However, detailed statistical analysis plans for safety endpoints are not presented."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 1 is identified by clinical trial registry number NCT01000974. Adverse reaction rates are presented in detailed tables. However, the 7 additional studies are not identified by registry number.",
            "level_description": "Some transparency is provided through the NCT registry number for Study 1 and detailed adverse event tables. However, full data availability, access to raw data, or complete study protocols are not addressed. Several supporting studies lack registry identification."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Section 6.2 documents postmarketing experience including: 'Extensive swelling of the vaccinated limb, injection site induration,' 'Allergic reactions (including anaphylactic and anaphylactoid reactions), angioedema,' 'Convulsions (with or without fever), hypotonic-hyporesponsive episode,' and 'Apnea.'",
            "level_description": "A dedicated postmarketing surveillance section documents additional adverse reactions identified after approval. VAERS reporting is referenced. However, frequency estimates cannot be made from voluntary reports, as acknowledged in the document."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document identifies the manufacturer as GlaxoSmithKline Biologicals but does not disclose investigator conflicts of interest, funding sources for independent analyses, or relationships between trial investigators and the sponsor.",
            "level_description": "No information is provided about conflicts of interest for study investigators, independent oversight committees, or financial relationships. The manufacturer conducted the trials, but transparency about potential bias is not addressed."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document does not report any deaths or all-cause mortality data from the clinical trials.",
            "level_description": "All-cause mortality is not addressed in the prescribing information. While specific serious adverse events are mentioned (convulsions, febrile seizures), there is no systematic reporting of deaths or mortality comparisons between treatment groups."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "The Hiberix clinical program included a reasonably sized randomized controlled trial (Study 1, n=2,963 for HIBERIX) with standardized adverse event collection and documented statistical methodology for immunogenicity. However, significant limitations include: (1) use of active vaccine comparators rather than true placebo controls, (2) very short follow-up period of only 4 days for solicited reactions and 31 days for serious events, (3) open-label design in several supporting studies, (4) no data on vulnerable populations like immunocompromised or premature infants, (5) no reporting of all-cause mortality, and (6) absent conflict of interest disclosures. The postmarketing surveillance section provides additional safety signals but cannot establish causality or frequency. Overall, the evidence base meets minimum regulatory standards but has meaningful gaps for comprehensive safety assessment."
        }
      },
      "trial_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O Estudo 1 comparou HIBERIX (n=2.963) com comparadores ativos: PRP-T de Controle (Sanofi Pasteur SA) (n=520) e DTaP-IPV/Hib (Sanofi Pasteur Ltd.) (n=520). Nenhum grupo placebo inerte foi utilizado.",
            "level_description": "Os ensaios cl√≠nicos utilizaram comparadores de vacinas ativas em vez de controles com placebo salino. Todos os grupos de compara√ß√£o receberam outras vacinas contendo Hib, tornando imposs√≠vel avaliar o verdadeiro perfil de seguran√ßa do HIBERIX em rela√ß√£o a uma linha de base n√£o vacinada."
          },
          "double_blind": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 1 √© descrito como 'ensaio cl√≠nico randomizado e controlado', mas o cegamento n√£o √© explicitamente mencionado. O Estudo 2 √© descrito como 'estudo multic√™ntrico aberto'.",
            "level_description": "O principal Estudo 1 nos EUA parece ser randomizado, mas a metodologia de cegamento n√£o est√° documentada. O Estudo 2 e os 7 estudos adicionais foram explicitamente abertos, significando que os investigadores e participantes sabiam qual vacina estava sendo administrada."
          },
          "randomization": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 1 √© descrito como 'um ensaio cl√≠nico randomizado e controlado conduzido nos EUA' com crian√ßas randomizadas para receber HIBERIX (n=2.963), PRP-T de Controle (n=520) ou DTaP-IPV/Hib (n=520).",
            "level_description": "A randomiza√ß√£o √© explicitamente declarada para o principal ensaio dos EUA (Estudo 1). No entanto, a metodologia de randomiza√ß√£o, oculta√ß√£o da aloca√ß√£o e detalhes de estratifica√ß√£o n√£o s√£o fornecidos."
          },
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "O Estudo 1 incluiu 2.963 crian√ßas recebendo HIBERIX para a s√©rie prim√°ria e 2.336 para a dose de refor√ßo. Sete estudos adicionais inclu√≠ram 1.008 crian√ßas recebendo HIBERIX como refor√ßo. O Estudo 2 incluiu 371 crian√ßas.",
            "level_description": "O tamanho total da amostra pedi√°trica entre os estudos foi substancial (mais de 4.000 crian√ßas recebendo HIBERIX). O principal ensaio dos EUA teve quase 3.000 participantes no bra√ßo HIBERIX, o que √© adequado para detectar rea√ß√µes adversas comuns."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Rea√ß√µes adversas solicitadas foram coletadas 'dentro de 4 dias da vacina√ß√£o'. Rea√ß√µes adversas graves nos 7 estudos adicionais foram relatadas 'no per√≠odo de 31 dias ap√≥s a imuniza√ß√£o de refor√ßo'.",
            "level_description": "O acompanhamento ativo para rea√ß√µes solicitadas foi extremamente curto, de apenas 4 dias p√≥s-vacina√ß√£o. O monitoramento de eventos adversos graves se estendeu a 31 dias em alguns estudos, mas nenhum acompanhamento de seguran√ßa a longo prazo (meses a anos) est√° documentado para efeitos adversos cr√¥nicos ou tardios."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A s√©rie prim√°ria foi administrada aos 2, 4 e 6 meses. O refor√ßo foi administrado entre 15-18 meses. Em 7 estudos adicionais, '172 (17,1%) participantes tinham entre 11 e 14 meses, 642 (63,7%) participantes tinham entre 15 e 18 meses, e 194 (19,2%) participantes tinham entre 19 e 25 meses'.",
            "level_description": "A distribui√ß√£o et√°ria est√° documentada para os estudos de refor√ßo, mas an√°lises de seguran√ßa separadas por subgrupo et√°rio n√£o s√£o apresentadas. Os resultados s√£o agregados entre os grupos et√°rios em vez de estratificados para compara√ß√£o."
          },
          "inclusion_exclusion_criteria": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento menciona contraindica√ß√µes (rea√ß√£o al√©rgica grave ap√≥s vacina Hib ou toxoide tet√¢nico anterior) e advert√™ncias (s√≠ndrome de Guillain-Barr√© dentro de 6 semanas, beb√™s prematuros, crian√ßas imunossuprimidas), mas n√£o detalha os crit√©rios espec√≠ficos de inclus√£o/exclus√£o dos ensaios.",
            "level_description": "Embora contraindica√ß√µes e precau√ß√µes sejam listadas para uso cl√≠nico, os crit√©rios reais de elegibilidade dos ensaios cl√≠nicos (crit√©rios espec√≠ficos de inclus√£o/exclus√£o usados para triagem de participantes) n√£o est√£o documentados na bula."
          },
          "standardized_adverse_events": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Rea√ß√µes solicitadas foram sistematicamente coletadas com gradua√ß√£o padronizada: dor Grau 3 'chorou quando o membro foi movido/espontaneamente doloroso', irritabilidade Grau 3 'choro que n√£o podia ser consolado/impedia atividade normal', febre Grau 3 '>103,1F (>39,5C) retal'.",
            "level_description": "Os ensaios utilizaram defini√ß√µes padronizadas e escalas de gradua√ß√£o para eventos adversos solicitados, com defini√ß√µes claras de Grau 3 fornecidas para rea√ß√µes locais e sist√™micas. Di√°rios ou ferramentas de coleta padronizadas parecem ter sido utilizados."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Rea√ß√µes adversas graves foram relatadas: 'Um de 2.963 participantes... experimentou uma rea√ß√£o adversa grave... convuls√£o no Dia 14 ap√≥s a Dose 1.' 'Um de 2.336 participantes... experimentou... nova convuls√£o febril no Dia 1 ap√≥s a Dose 4.' Nos 7 estudos adicionais, '2 de 1.008 participantes relataram uma rea√ß√£o adversa grave... no per√≠odo de 31 dias ap√≥s a imuniza√ß√£o de refor√ßo'.",
            "level_description": "Eventos adversos graves foram capturados durante os ensaios com associa√ß√µes temporais observadas. No entanto, a metodologia para monitoramento ativo (frequ√™ncia de contato, m√©todos de verifica√ß√£o) n√£o √© descrita. A janela de monitoramento de 31 dias √© relativamente curta para detectar rea√ß√µes graves tardias."
          },
          "autoimmune_neurological": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A s√≠ndrome de Guillain-Barr√© √© mencionada como advert√™ncia se ocorreu dentro de 6 semanas de vacina contendo t√©tano anterior. Relatos p√≥s-comercializa√ß√£o incluem 'Convuls√µes (com ou sem febre), epis√≥dio hipot√¥nico-hiporresponsivo (ou seja, in√≠cio s√∫bito de hipotonia, hiporresponsividade e palidez ou cianose)'.",
            "level_description": "Eventos neurol√≥gicos s√£o abordados nas se√ß√µes de advert√™ncias e p√≥s-comercializa√ß√£o, mas a avalia√ß√£o proativa de desfechos autoimunes ou neurol√≥gicos nos ensaios cl√≠nicos n√£o est√° documentada. A precau√ß√£o sobre Guillain-Barr√© refere-se ao hist√≥rico anterior, n√£o ao monitoramento do ensaio."
          },
          "vulnerable_subgroups": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Advert√™ncias observam: 'A seguran√ßa e efic√°cia do HIBERIX em crian√ßas imunossuprimidas n√£o foram avaliadas.' 'Apneia ap√≥s vacina√ß√£o intramuscular foi observada em alguns beb√™s nascidos prematuramente'.",
            "level_description": "Popula√ß√µes vulner√°veis, como crian√ßas imunocomprometidas e beb√™s prematuros, explicitamente n√£o foram estudadas. O documento reconhece essas lacunas, mas n√£o fornece dados de seguran√ßa para esses subgrupos de alto risco dos ensaios cl√≠nicos."
          },
          "statistical_analysis": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "An√°lises de n√£o inferioridade foram realizadas: 'HIBERIX foi n√£o inferior ao PRP-T de Controle para a porcentagem de participantes atingindo anti-PRP >=0,15 mcg/mL (limite inferior do IC 95% na diferen√ßa de HIBERIX menos PRP-T de Controle >= limite predefinido de -5%)'.",
            "level_description": "A metodologia estat√≠stica para compara√ß√µes de n√£o inferioridade de imunogenicidade est√° documentada com intervalos de confian√ßa e margens de n√£o inferioridade predefinidas. No entanto, planos de an√°lise estat√≠stica detalhados para desfechos de seguran√ßa n√£o s√£o apresentados."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 1 √© identificado pelo n√∫mero de registro de ensaio cl√≠nico NCT01000974. As taxas de rea√ß√µes adversas s√£o apresentadas em tabelas detalhadas. No entanto, os 7 estudos adicionais n√£o s√£o identificados por n√∫mero de registro.",
            "level_description": "Alguma transpar√™ncia √© fornecida atrav√©s do n√∫mero de registro NCT para o Estudo 1 e tabelas detalhadas de eventos adversos. No entanto, disponibilidade completa de dados, acesso a dados brutos ou protocolos completos de estudo n√£o s√£o abordados. V√°rios estudos de apoio carecem de identifica√ß√£o de registro."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "A Se√ß√£o 6.2 documenta a experi√™ncia p√≥s-comercializa√ß√£o incluindo: 'Incha√ßo extenso do membro vacinado, indura√ß√£o no local da inje√ß√£o', 'Rea√ß√µes al√©rgicas (incluindo rea√ß√µes anafil√°ticas e anafilactoides), angioedema', 'Convuls√µes (com ou sem febre), epis√≥dio hipot√¥nico-hiporresponsivo' e 'Apneia'.",
            "level_description": "Uma se√ß√£o dedicada √† vigil√¢ncia p√≥s-comercializa√ß√£o documenta rea√ß√µes adversas adicionais identificadas ap√≥s a aprova√ß√£o. O relat√≥rio VAERS √© referenciado. No entanto, estimativas de frequ√™ncia n√£o podem ser feitas a partir de relatos volunt√°rios, conforme reconhecido no documento."
          },
          "conflict_of_interest": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento identifica o fabricante como GlaxoSmithKline Biologicals, mas n√£o divulga conflitos de interesse dos investigadores, fontes de financiamento para an√°lises independentes ou relacionamentos entre os investigadores do ensaio e o patrocinador.",
            "level_description": "Nenhuma informa√ß√£o √© fornecida sobre conflitos de interesse para investigadores do estudo, comit√™s de supervis√£o independentes ou relacionamentos financeiros. O fabricante conduziu os ensaios, mas a transpar√™ncia sobre potencial vi√©s n√£o √© abordada."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento n√£o relata nenhuma morte ou dados de mortalidade por todas as causas dos ensaios cl√≠nicos.",
            "level_description": "A mortalidade por todas as causas n√£o √© abordada na bula. Embora eventos adversos graves espec√≠ficos sejam mencionados (convuls√µes, convuls√µes febris), n√£o h√° relato sistem√°tico de mortes ou compara√ß√µes de mortalidade entre os grupos de tratamento."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "O programa cl√≠nico do Hiberix incluiu um ensaio controlado randomizado de tamanho razo√°vel (Estudo 1, n=2.963 para HIBERIX) com coleta padronizada de eventos adversos e metodologia estat√≠stica documentada para imunogenicidade. No entanto, limita√ß√µes significativas incluem: (1) uso de comparadores de vacinas ativas em vez de controles com placebo verdadeiro, (2) per√≠odo de acompanhamento muito curto de apenas 4 dias para rea√ß√µes solicitadas e 31 dias para eventos graves, (3) desenho aberto em v√°rios estudos de apoio, (4) aus√™ncia de dados sobre popula√ß√µes vulner√°veis como beb√™s imunocomprometidos ou prematuros, (5) aus√™ncia de relato de mortalidade por todas as causas, e (6) aus√™ncia de divulga√ß√µes de conflitos de interesse. A se√ß√£o de vigil√¢ncia p√≥s-comercializa√ß√£o fornece sinais de seguran√ßa adicionais, mas n√£o pode estabelecer causalidade ou frequ√™ncia. No geral, a base de evid√™ncias atende aos padr√µes regulat√≥rios m√≠nimos, mas possui lacunas significativas para uma avalia√ß√£o abrangente de seguran√ßa."
        }
      },
      "safety_en": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Study 1 enrolled a substantial pediatric population: 2,963 children received HIBERIX for the primary series (at 2, 4, and 6 months), and 2,336 received the booster dose at 15-18 months. Control groups included 520 children each for Control PRP-T and DTaP-IPV/Hib. Seven additional studies contributed 1,008 children who received HIBERIX as a booster dose. The demographic breakdown shows 51.2% male, 61% white, 8% Asian, 9% black, and 22% other racial/ethnic groups. The total population across all trials is approximately 4,000+ children, which is adequate for detecting common adverse reactions."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Solicited adverse reactions were only collected within 4 days of vaccination (day of vaccination and the next 3 days). Serious adverse reactions were monitored for 31 days post-immunization in the 7 additional studies. There is no evidence of long-term safety follow-up extending months or years post-vaccination. This short follow-up window is insufficient to detect delayed adverse events or long-term safety signals."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Study 1 was a randomized, controlled clinical trial comparing HIBERIX against two active comparators: a U.S.-licensed monovalent Haemophilus b Conjugate Vaccine (Control PRP-T from Sanofi Pasteur SA) with n=520, and a U.S.-licensed combined DTaP-IPV/Hib vaccine (Sanofi Pasteur Ltd.) with n=520. While this uses active controls rather than placebo, it allows for direct comparison of safety profiles against established vaccines. However, it should be noted that seven additional studies lacked a comparator group receiving a U.S.-licensed Haemophilus b Conjugate Vaccine."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The trials employed active solicitation of adverse reactions. Solicited local reactions (pain, redness, swelling) and general adverse reactions (irritability, drowsiness, fever, loss of appetite, fussiness, restlessness) were systematically collected within 4 days of vaccination. The insert includes detailed tables (Tables 1, 2, and 3) with specific percentages for each adverse reaction by dose and grade severity. Grade 3 (severe) reactions were specifically tracked. This demonstrates structured active surveillance methodology, though limited to a 4-day window."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Neurological safety concerns are addressed but incompletely. Guillain-Barre Syndrome (GBS) is mentioned as a warning, noting that if GBS occurred within 6 weeks of a prior tetanus toxoid-containing vaccine, the decision to give HIBERIX should be based on risk-benefit analysis. Syncope with transient neurological signs (visual disturbance, paresthesia, tonic-clonic limb movements) is documented. Serious adverse reactions included 1 convulsion on Day 14 after Dose 1 (1/2,963) and 1 new onset febrile seizure on Day 1 after Dose 4 (1/2,336). Postmarketing reports include convulsions (with or without fever) and hypotonic-hyporesponsive episodes. However, there is no systematic neurological assessment protocol or long-term neurological follow-up described in the clinical trials."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Some vulnerable populations are addressed but with limitations. Premature infants: A warning notes that apnea following intramuscular vaccination has been observed in some infants born prematurely, advising individual risk-benefit assessment. Immunocompromised children: The insert states that safety and effectiveness in immunosuppressed children have not been evaluated, acknowledging this gap. The pediatric age range is specifically defined (6 weeks through 4 years). However, the document explicitly states safety and effectiveness have not been established in children younger than 6 weeks or aged 5-16 years. No specific data is provided for children with chronic illnesses or other high-risk conditions."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "The insert provides substantial transparent safety data: detailed tables showing adverse reaction percentages by dose number and severity grade; breakdown of sample sizes for each study arm; demographic information (sex, race/ethnicity); specific NCT trial identifier (NCT01000974) for Study 1; clear definitions of grading scales (e.g., Grade 3 pain defined as 'cried when limb was moved/spontaneously painful'); and temperature thresholds for fever definitions. Geographic locations of additional studies (Europe, Canada, Latin America, Germany) are disclosed. However, raw data and confidence intervals for adverse reactions are not provided."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Section 6.2 documents postmarketing experience with specific adverse reactions identified after approval, including: extensive swelling of vaccinated limb, injection site induration, allergic reactions (including anaphylactic/anaphylactoid reactions), angioedema, convulsions (with or without fever), hypotonic-hyporesponsive episodes, somnolence, syncope, vasovagal responses, apnea, rash, and urticaria. The insert appropriately notes that voluntary reporting makes it impossible to reliably estimate frequency or establish causal relationships. VAERS reporting information is provided (1-800-822-7967). Manufacturer contact for reporting is included (GlaxoSmithKline at 1-888-825-5249)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "HIBERIX demonstrates adequate safety documentation in several areas: substantial pediatric sample size (~4,000+ children), randomized controlled comparison against licensed vaccines, active solicitation of adverse reactions with detailed severity grading, reasonable data transparency with published trial identifiers, and established postmarketing surveillance. However, significant limitations exist: follow-up duration is critically short (only 4 days for solicited reactions, 31 days for serious events), with no long-term safety monitoring. Neurological monitoring captured some serious events (convulsions, febrile seizures) but lacks systematic neurological assessment protocols. Vulnerable populations like immunocompromised children explicitly lack safety data. Overall, the safety profile is reasonably documented for short-term common reactions but insufficient for detecting delayed or rare adverse events."
        }
      },
      "safety_pt": {
        "vaccine_id": "hib_hiberix",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo 1 incluiu uma popula√ß√£o pedi√°trica substancial: 2.963 crian√ßas receberam HIBERIX para a s√©rie prim√°ria (aos 2, 4 e 6 meses), e 2.336 receberam a dose de refor√ßo aos 15-18 meses. Os grupos controle inclu√≠ram 520 crian√ßas cada para o Controle PRP-T e DTaP-IPV/Hib. Sete estudos adicionais contribu√≠ram com 1.008 crian√ßas que receberam HIBERIX como dose de refor√ßo. A distribui√ß√£o demogr√°fica mostra 51,2% masculino, 61% brancos, 8% asi√°ticos, 9% negros e 22% outros grupos raciais/√©tnicos. A popula√ß√£o total em todos os ensaios √© de aproximadamente 4.000+ crian√ßas, o que √© adequado para detectar rea√ß√µes adversas comuns."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "As rea√ß√µes adversas solicitadas foram coletadas apenas dentro de 4 dias ap√≥s a vacina√ß√£o (dia da vacina√ß√£o e os 3 dias seguintes). Rea√ß√µes adversas graves foram monitoradas por 31 dias ap√≥s a imuniza√ß√£o nos 7 estudos adicionais. N√£o h√° evid√™ncia de acompanhamento de seguran√ßa a longo prazo estendendo-se por meses ou anos ap√≥s a vacina√ß√£o. Esta janela curta de acompanhamento √© insuficiente para detectar eventos adversos tardios ou sinais de seguran√ßa a longo prazo."
          },
          "comparison_group": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "O Estudo 1 foi um ensaio cl√≠nico randomizado e controlado comparando HIBERIX contra dois comparadores ativos: uma Vacina Conjugada Haemophilus b monovalente licenciada nos EUA (Controle PRP-T da Sanofi Pasteur SA) com n=520, e uma vacina combinada DTaP-IPV/Hib licenciada nos EUA (Sanofi Pasteur Ltd.) com n=520. Embora use controles ativos em vez de placebo, permite compara√ß√£o direta dos perfis de seguran√ßa contra vacinas estabelecidas. No entanto, deve-se notar que sete estudos adicionais n√£o inclu√≠ram um grupo comparador recebendo uma Vacina Conjugada Haemophilus b licenciada nos EUA."
          },
          "active_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "Os ensaios empregaram solicita√ß√£o ativa de rea√ß√µes adversas. Rea√ß√µes locais solicitadas (dor, vermelhid√£o, incha√ßo) e rea√ß√µes adversas gerais (irritabilidade, sonol√™ncia, febre, perda de apetite, agita√ß√£o, inquieta√ß√£o) foram sistematicamente coletadas dentro de 4 dias ap√≥s a vacina√ß√£o. A bula inclui tabelas detalhadas (Tabelas 1, 2 e 3) com porcentagens espec√≠ficas para cada rea√ß√£o adversa por dose e gravidade. Rea√ß√µes Grau 3 (graves) foram especificamente rastreadas. Isso demonstra metodologia de vigil√¢ncia ativa estruturada, embora limitada a uma janela de 4 dias."
          },
          "neurological_monitoring": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Preocupa√ß√µes de seguran√ßa neurol√≥gica s√£o abordadas, mas de forma incompleta. A S√≠ndrome de Guillain-Barr√© (SGB) √© mencionada como advert√™ncia, observando que se a SGB ocorreu dentro de 6 semanas de uma vacina pr√©via contendo toxoide tet√¢nico, a decis√£o de administrar HIBERIX deve ser baseada na an√°lise de risco-benef√≠cio. S√≠ncope com sinais neurol√≥gicos transit√≥rios (dist√∫rbio visual, parestesia, movimentos t√¥nico-cl√¥nicos dos membros) est√° documentada. Rea√ß√µes adversas graves inclu√≠ram 1 convuls√£o no Dia 14 ap√≥s a Dose 1 (1/2.963) e 1 nova crise febril no Dia 1 ap√≥s a Dose 4 (1/2.336). Relatos p√≥s-comercializa√ß√£o incluem convuls√µes (com ou sem febre) e epis√≥dios hipot√¥nico-hiporresponsivos. No entanto, n√£o h√° protocolo sistem√°tico de avalia√ß√£o neurol√≥gica ou acompanhamento neurol√≥gico a longo prazo descrito nos ensaios cl√≠nicos."
          },
          "vulnerable_subgroups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Algumas popula√ß√µes vulner√°veis s√£o abordadas, mas com limita√ß√µes. Beb√™s prematuros: Uma advert√™ncia observa que apneia ap√≥s vacina√ß√£o intramuscular foi observada em alguns beb√™s nascidos prematuramente, aconselhando avalia√ß√£o individual de risco-benef√≠cio. Crian√ßas imunocomprometidas: A bula afirma que seguran√ßa e efic√°cia em crian√ßas imunossuprimidas n√£o foram avaliadas, reconhecendo essa lacuna. A faixa et√°ria pedi√°trica √© especificamente definida (6 semanas a 4 anos). No entanto, o documento declara explicitamente que seguran√ßa e efic√°cia n√£o foram estabelecidas em crian√ßas menores de 6 semanas ou com idade entre 5-16 anos. Nenhum dado espec√≠fico √© fornecido para crian√ßas com doen√ßas cr√¥nicas ou outras condi√ß√µes de alto risco."
          },
          "data_transparency": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A bula fornece dados de seguran√ßa transparentes substanciais: tabelas detalhadas mostrando porcentagens de rea√ß√µes adversas por n√∫mero de dose e grau de gravidade; discrimina√ß√£o dos tamanhos de amostra para cada bra√ßo do estudo; informa√ß√µes demogr√°ficas (sexo, ra√ßa/etnia); identificador espec√≠fico do ensaio NCT (NCT01000974) para o Estudo 1; defini√ß√µes claras de escalas de gradua√ß√£o (por exemplo, dor Grau 3 definida como 'chorou quando o membro foi movido/dor espont√¢nea'); e limites de temperatura para defini√ß√µes de febre. Localiza√ß√µes geogr√°ficas dos estudos adicionais (Europa, Canad√°, Am√©rica Latina, Alemanha) s√£o divulgadas. No entanto, dados brutos e intervalos de confian√ßa para rea√ß√µes adversas n√£o s√£o fornecidos."
          },
          "post_marketing_surveillance": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "explanation": "A Se√ß√£o 6.2 documenta experi√™ncia p√≥s-comercializa√ß√£o com rea√ß√µes adversas espec√≠ficas identificadas ap√≥s a aprova√ß√£o, incluindo: incha√ßo extenso do membro vacinado, endurecimento no local da inje√ß√£o, rea√ß√µes al√©rgicas (incluindo rea√ß√µes anafil√°ticas/anafilactoides), angioedema, convuls√µes (com ou sem febre), epis√≥dios hipot√¥nico-hiporresponsivos, sonol√™ncia, s√≠ncope, respostas vasovagais, apneia, erup√ß√£o cut√¢nea e urtic√°ria. A bula observa apropriadamente que o relato volunt√°rio torna imposs√≠vel estimar confiavelmente a frequ√™ncia ou estabelecer rela√ß√µes causais. Informa√ß√µes de relato ao VAERS s√£o fornecidas (1-800-822-7967). Contato do fabricante para relatos est√° inclu√≠do (GlaxoSmithKline em 1-888-825-5249)."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "HIBERIX demonstra documenta√ß√£o de seguran√ßa adequada em v√°rias √°reas: tamanho de amostra pedi√°trica substancial (~4.000+ crian√ßas), compara√ß√£o controlada randomizada contra vacinas licenciadas, solicita√ß√£o ativa de rea√ß√µes adversas com gradua√ß√£o detalhada de gravidade, transpar√™ncia razo√°vel de dados com identificadores de ensaios publicados e vigil√¢ncia p√≥s-comercializa√ß√£o estabelecida. No entanto, existem limita√ß√µes significativas: a dura√ß√£o do acompanhamento √© criticamente curta (apenas 4 dias para rea√ß√µes solicitadas, 31 dias para eventos graves), sem monitoramento de seguran√ßa a longo prazo. O monitoramento neurol√≥gico capturou alguns eventos graves (convuls√µes, crises febris), mas carece de protocolos sistem√°ticos de avalia√ß√£o neurol√≥gica. Popula√ß√µes vulner√°veis como crian√ßas imunocomprometidas explicitamente carecem de dados de seguran√ßa. No geral, o perfil de seguran√ßa est√° razoavelmente documentado para rea√ß√µes comuns de curto prazo, mas √© insuficiente para detectar eventos adversos tardios ou raros."
        }
      }
    },
    {
      "id": "mmr_mmrii",
      "name": "M-M-R II",
      "type": "MMR",
      "manufacturer": "Merck",
      "description": "Measles, Mumps, and Rubella Virus Vaccine Live (RA 27/3 strain) for prevention of measles, mumps, and rubella. Originally licensed September 1978. Source document is 1978 FDA FOIA clinical trial summary.",
      "sources": [
        "mmr_mmrii_clinical.pdf"
      ],
      "trial_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "en",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The main licensure studies (442, 443, 467, 511, 513) compared M-M-R (RA 27/3) against other active vaccines: measles-rubella vaccine, rubella-only vaccine, or M-M-R with HPV-77 rubella strain. Study 459 protocol mentions a placebo group of 50 children in the study design, but this was only 9% of the total 550 planned subjects, with remaining children receiving various active vaccine formulations.",
            "level_description": "The clinical studies supporting M-M-R II licensure primarily compared different vaccine formulations (RA 27/3 vs HPV-77 rubella strains, combined vs single-component vaccines) rather than using true inert placebo controls. While Study 459 mentions a small placebo group (50/550), the overall safety assessment was based on active comparators, making it impossible to determine the true baseline rate of adverse events attributable to the vaccine versus coincidental events."
          },
          "double_blind": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "The document does not describe blinding procedures for any of the main studies (442, 443, 467, 511, 513). Study 459 mentions that 'coded vials' were supplied by Merck Sharp & Dohme, suggesting some potential for blinding, but explicit blinding methodology is not described.",
            "level_description": "No explicit double-blinding is documented for the clinical trials. The studies appear to be predominantly open-label, with investigators and participants potentially aware of which vaccine formulation was administered. The mention of 'coded vials' in one study is insufficient evidence of proper double-blinding procedures."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Study 459 states children will be 'randomly assigned' to receive one of the vaccine groups. However, most other studies (442, 443, 467, 511, 513) describe children being 'assigned' or receiving vaccines without explicit mention of randomization methodology.",
            "level_description": "Randomization is mentioned for Study 459, but the allocation method, concealment procedures, and stratification are not documented. Other major studies lack explicit documentation of randomization. The methodology falls short of demonstrating proper random allocation with concealment."
          },
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Total vaccinations documented: 834 children received combined live M-M-R (RA 27/3) vaccine across lot numbers 621, 60664, 60665, and 60666. Individual studies: Study 442 (199 children with MMR), Study 443 (102 children with MMR), Study 467 (269 children), Study 511 (226 children), Study 513 (163 children).",
            "level_description": "The total sample size of approximately 834 children is grossly inadequate for detecting rare adverse events. Standard safety assessment requires at least 3,000 children per age group to detect events occurring at 1:1,000 frequency with statistical confidence. This sample size could only reliably detect adverse events occurring more frequently than approximately 1 in 100 children."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All studies followed children for 42 days (6 weeks) post-vaccination. Blood samples were obtained 'six weeks after vaccination' for serological testing. Clinical surveillance recorded complaints for '42 days following vaccination.'",
            "level_description": "The 42-day (6-week) follow-up period is severely inadequate for detecting delayed adverse reactions, particularly autoimmune conditions, neurological complications, or other chronic sequelae that may emerge weeks to months after vaccination. Modern safety standards require minimum 6-12 months of follow-up, with ideal multi-year surveillance for pediatric vaccines."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Children ranged from 10 months to 8 years of age across studies. Mean ages were documented: Study 442 (3.7 years), Study 443 (1.7 years), Study 467 (1.9 years). Some tables break down serological results by individual age years (10 months, 11 months, 1 year, 2 years, etc.).",
            "level_description": "While age data is collected and some tables show results by individual ages, the studies do not provide formal stratified safety analyses by distinct developmental age groups (infants 0-12 months, toddlers 1-2 years, preschoolers 3-5 years). Aggregated safety data may mask age-specific reaction patterns."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Documented exclusion criteria: sensitivity to egg, chicken, chicken feathers, or neomycin; leukemia or other immunologic disorders; persons receiving immunosuppressive drugs; febrile respiratory illness or other active febrile infection. Children were required to have negative history for vaccination with and illness caused by viruses represented in the vaccine.",
            "level_description": "The studies document clear exclusion criteria related to allergies, immunocompromised status, and concurrent illness. Entry criteria required negative disease and vaccination history. While these criteria are documented, the exclusion of children with chronic conditions limits generalizability to real-world populations."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Clinical complaints were categorized into: fever (by temperature ranges: <99F, 99-100.9F, 101-102.9F, 103-104.9F, >105F), irritability, malaise, headache, upper respiratory illness, otitis, ophthalmopathy, gastrointestinal illness, anorexia, rash, lymphadenopathy, myalgia, arthralgia. Temperature was recorded as oral or rectal.",
            "level_description": "The studies used consistent categories for adverse event reporting with temperature grading. However, no standardized criteria such as Brighton Collaboration definitions or MedDRA coding were used (predating these standards). Subjective categories like 'irritability' and 'malaise' lacked objective thresholds. Modern standardized adverse event definitions were not available in 1978."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Protocols state: 'Any serious or alarming reaction, including death due to any cause during the investigation, whether related or not related to the test material, must be reported immediately to Merck & Co., Inc.' Parents were asked to 'contact the physician should any significant or bothersome reaction occur.' In some studies, observations were made by 'medical or paramedical personnel.'",
            "level_description": "There was a passive reporting mechanism for serious events with instructions to report deaths and serious reactions. However, this relied on parental observation and voluntary reporting rather than systematic active surveillance with scheduled clinical assessments. The methodology for serious adverse event ascertainment falls short of active monitoring standards."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "No mention of autoimmune conditions, encephalitis, Guillain-Barre syndrome, seizures, convulsions, or other neurological assessments in the clinical trial documentation. High fevers (up to 105F) were documented in some children, but neurological evaluation was not described.",
            "level_description": "The clinical trials did not include any specific monitoring, assessment, or reporting of autoimmune or neurological adverse events. Given that MMR vaccine has subsequently been associated with rare cases of febrile seizures, immune thrombocytopenic purpura, and encephalitis, the absence of any such monitoring in the original trials represents a significant gap."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Children with leukemia, immunologic disorders, or receiving immunosuppressive drugs were explicitly excluded from the trials. No separate analysis or inclusion of premature infants, children with allergies, chronic diseases, or other vulnerable populations is documented.",
            "level_description": "Vulnerable subgroups were systematically excluded from the clinical trials rather than studied. There is no safety data from the pre-licensure trials for immunocompromised children, premature infants, or children with chronic health conditions who would subsequently receive this vaccine in real-world use."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "A memo describes 'Analysis of variance was conducted on post titers' comparing rubella vaccine groups. Seroconversion rates and geometric mean titers are reported with percentages. One memo states 'No significant difference exists among the three groups.'",
            "level_description": "Basic statistical analysis (ANOVA, seroconversion rates, geometric mean titers) was performed for immunogenicity outcomes. However, no power calculations for safety detection are documented, and the small sample sizes preclude meaningful statistical analysis of adverse events. The studies were powered for efficacy, not safety."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "The document was released through a FOIA request dated August 2019, over 40 years after the 1978 licensure. The cover letter notes that 'portions of pages' were withheld under Exemption 4 (trade secrets) and Exemption 6 (personal privacy). Detailed background records were stated to be 'on file in Virus and Cell Biology Research, Merck Institute.'",
            "level_description": "This document was obtained only through FOIA request decades after approval, with portions redacted. Individual patient data are not publicly available. No independent Data Safety Monitoring Board is mentioned. The delayed and partial release of clinical trial data limits independent verification of safety findings."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "The document covers pre-licensure clinical trials only. No post-marketing surveillance plan, passive reporting system (such as VAERS, which did not exist until 1990), or ongoing safety monitoring is described.",
            "level_description": "The 1978 licensure document contains no post-marketing surveillance provisions. VAERS was not established until 1990. The complete absence of post-marketing safety monitoring in the original approval documents means the safety assessment relied entirely on the limited pre-licensure trials."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "All clinical studies were conducted under the overall responsibility of Dr. Maurice R. Hilleman, Vice President, Virus and Cell Biology Research, Merck Institute for Therapeutic Research. Vaccines were prepared by Merck Sharp and Dohme Biologics Manufacturing. Serologic testing was performed in Merck laboratories. Clinical investigators reported directly to Merck.",
            "level_description": "The trials were entirely designed, managed, and analyzed by the vaccine manufacturer. The lead investigator was a Vice President at Merck. No independent oversight, external monitoring, or disclosure of financial relationships is documented. This represents a fundamental conflict of interest with no mitigation measures described."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Protocols mention that 'death due to any cause during the investigation, whether related or not related to the test material, must be reported immediately.' However, no mortality data, death reports, or systematic mortality analysis appears in the results documentation.",
            "level_description": "While the protocol required death reporting, no mortality data is presented in the clinical trial results. There is no systematic comparison of all-cause mortality between vaccine groups or documentation of whether any deaths occurred during the 42-day follow-up period."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "The 1978 M-M-R II licensure studies demonstrate significant methodological limitations by any safety assessment standard. The trials enrolled only approximately 834 children receiving the combined vaccine, far below the minimum 3,000 per age group needed to detect rare adverse events. Follow-up was limited to 42 days, precluding detection of delayed autoimmune or neurological reactions. No true placebo control was used - instead comparing different vaccine formulations. Studies lacked double-blinding, with most appearing to be open-label. The trials excluded vulnerable populations (immunocompromised, premature infants) who would later receive the vaccine. No assessment of autoimmune or neurological outcomes was performed despite these being subsequently identified as rare adverse events. The entire research program was conducted by the manufacturer with no independent oversight, representing an unmitigated conflict of interest. While the studies may have been standard for their era, they fall dramatically short of modern pediatric vaccine safety evaluation requirements and leave substantial uncertainty about the true adverse event profile of M-M-R II."
        }
      },
      "trial_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "trial",
        "language": "pt",
        "criteria": {
          "placebo_control": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Os principais estudos de licenciamento (442, 443, 467, 511, 513) compararam a M-M-R (RA 27/3) com outras vacinas ativas: vacina sarampo-rub√©ola, vacina somente de rub√©ola, ou M-M-R com cepa de rub√©ola HPV-77. O protocolo do Estudo 459 menciona um grupo placebo de 50 crian√ßas no desenho do estudo, mas isso representava apenas 9% do total de 550 participantes planejados, com as crian√ßas restantes recebendo v√°rias formula√ß√µes de vacinas ativas.",
            "level_description": "Os estudos cl√≠nicos que fundamentaram o licenciamento da M-M-R II compararam principalmente diferentes formula√ß√µes de vacinas (cepas de rub√©ola RA 27/3 vs HPV-77, vacinas combinadas vs componentes √∫nicos) em vez de usar controles placebo verdadeiramente inertes. Embora o Estudo 459 mencione um pequeno grupo placebo (50/550), a avalia√ß√£o geral de seguran√ßa baseou-se em comparadores ativos, tornando imposs√≠vel determinar a verdadeira taxa basal de eventos adversos atribu√≠veis √† vacina versus eventos coincidentes."
          },
          "double_blind": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "O documento n√£o descreve procedimentos de cegamento para nenhum dos estudos principais (442, 443, 467, 511, 513). O Estudo 459 menciona que 'frascos codificados' foram fornecidos pela Merck Sharp & Dohme, sugerindo algum potencial para cegamento, mas a metodologia expl√≠cita de cegamento n√£o √© descrita.",
            "level_description": "N√£o h√° documenta√ß√£o expl√≠cita de duplo-cego para os ensaios cl√≠nicos. Os estudos parecem ser predominantemente abertos, com investigadores e participantes potencialmente cientes de qual formula√ß√£o de vacina foi administrada. A men√ß√£o de 'frascos codificados' em um estudo √© evid√™ncia insuficiente de procedimentos adequados de duplo-cego."
          },
          "randomization": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O Estudo 459 afirma que as crian√ßas ser√£o 'atribu√≠das aleatoriamente' para receber um dos grupos de vacina. No entanto, a maioria dos outros estudos (442, 443, 467, 511, 513) descreve crian√ßas sendo 'atribu√≠das' ou recebendo vacinas sem men√ß√£o expl√≠cita da metodologia de randomiza√ß√£o.",
            "level_description": "A randomiza√ß√£o √© mencionada para o Estudo 459, mas o m√©todo de aloca√ß√£o, procedimentos de oculta√ß√£o e estratifica√ß√£o n√£o est√£o documentados. Outros estudos importantes carecem de documenta√ß√£o expl√≠cita de randomiza√ß√£o. A metodologia n√£o demonstra adequadamente aloca√ß√£o aleat√≥ria apropriada com oculta√ß√£o."
          },
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Total de vacina√ß√µes documentadas: 834 crian√ßas receberam a vacina combinada M-M-R viva (RA 27/3) atrav√©s dos lotes 621, 60664, 60665 e 60666. Estudos individuais: Estudo 442 (199 crian√ßas com MMR), Estudo 443 (102 crian√ßas com MMR), Estudo 467 (269 crian√ßas), Estudo 511 (226 crian√ßas), Estudo 513 (163 crian√ßas).",
            "level_description": "O tamanho total da amostra de aproximadamente 834 crian√ßas √© grosseiramente inadequado para detectar eventos adversos raros. A avalia√ß√£o padr√£o de seguran√ßa requer pelo menos 3.000 crian√ßas por faixa et√°ria para detectar eventos que ocorrem na frequ√™ncia de 1:1.000 com confian√ßa estat√≠stica. Este tamanho de amostra s√≥ poderia detectar de forma confi√°vel eventos adversos que ocorrem com mais frequ√™ncia do que aproximadamente 1 em 100 crian√ßas."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos acompanharam as crian√ßas por 42 dias (6 semanas) ap√≥s a vacina√ß√£o. Amostras de sangue foram obtidas 'seis semanas ap√≥s a vacina√ß√£o' para testes sorol√≥gicos. A vigil√¢ncia cl√≠nica registrou queixas por '42 dias ap√≥s a vacina√ß√£o.'",
            "level_description": "O per√≠odo de acompanhamento de 42 dias (6 semanas) √© severamente inadequado para detectar rea√ß√µes adversas tardias, particularmente condi√ß√µes autoimunes, complica√ß√µes neurol√≥gicas ou outras sequelas cr√¥nicas que podem surgir semanas a meses ap√≥s a vacina√ß√£o. Os padr√µes modernos de seguran√ßa exigem um m√≠nimo de 6-12 meses de acompanhamento, com vigil√¢ncia ideal de m√∫ltiplos anos para vacinas pedi√°tricas."
          },
          "separate_age_groups": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As crian√ßas variaram de 10 meses a 8 anos de idade entre os estudos. Idades m√©dias foram documentadas: Estudo 442 (3,7 anos), Estudo 443 (1,7 anos), Estudo 467 (1,9 anos). Algumas tabelas apresentam resultados sorol√≥gicos por idades individuais (10 meses, 11 meses, 1 ano, 2 anos, etc.).",
            "level_description": "Embora os dados de idade sejam coletados e algumas tabelas mostrem resultados por idades individuais, os estudos n√£o fornecem an√°lises de seguran√ßa formalmente estratificadas por grupos et√°rios de desenvolvimento distintos (beb√™s 0-12 meses, crian√ßas pequenas 1-2 anos, pr√©-escolares 3-5 anos). Dados de seguran√ßa agregados podem mascarar padr√µes de rea√ß√£o espec√≠ficos por idade."
          },
          "inclusion_exclusion_criteria": {
            "rating": "adequate",
            "emoji": "‚úÖ",
            "what_document_states": "Crit√©rios de exclus√£o documentados: sensibilidade a ovo, frango, penas de frango ou neomicina; leucemia ou outros dist√∫rbios imunol√≥gicos; pessoas recebendo medicamentos imunossupressores; doen√ßa respirat√≥ria febril ou outra infec√ß√£o febril ativa. As crian√ßas deveriam ter hist√≥rico negativo para vacina√ß√£o e doen√ßa causada pelos v√≠rus representados na vacina.",
            "level_description": "Os estudos documentam crit√©rios de exclus√£o claros relacionados a alergias, estado imunocomprometido e doen√ßas concomitantes. Os crit√©rios de entrada exigiam hist√≥rico negativo de doen√ßa e vacina√ß√£o. Embora esses crit√©rios estejam documentados, a exclus√£o de crian√ßas com condi√ß√µes cr√¥nicas limita a generaliza√ß√£o para popula√ß√µes do mundo real."
          },
          "standardized_adverse_events": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "As queixas cl√≠nicas foram categorizadas em: febre (por faixas de temperatura: <99F, 99-100,9F, 101-102,9F, 103-104,9F, >105F), irritabilidade, mal-estar, dor de cabe√ßa, doen√ßa respirat√≥ria superior, otite, oftalmopatia, doen√ßa gastrointestinal, anorexia, erup√ß√£o cut√¢nea, linfadenopatia, mialgia, artralgia. A temperatura foi registrada como oral ou retal.",
            "level_description": "Os estudos usaram categorias consistentes para relato de eventos adversos com gradua√ß√£o de temperatura. No entanto, nenhum crit√©rio padronizado como defini√ß√µes da Brighton Collaboration ou codifica√ß√£o MedDRA foi usado (antecedendo esses padr√µes). Categorias subjetivas como 'irritabilidade' e 'mal-estar' n√£o tinham limiares objetivos. Defini√ß√µes modernas padronizadas de eventos adversos n√£o estavam dispon√≠veis em 1978."
          },
          "active_monitoring_serious": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Os protocolos afirmam: 'Qualquer rea√ß√£o s√©ria ou alarmante, incluindo morte por qualquer causa durante a investiga√ß√£o, relacionada ou n√£o ao material de teste, deve ser relatada imediatamente √† Merck & Co., Inc.' Os pais foram solicitados a 'contatar o m√©dico caso ocorra qualquer rea√ß√£o significativa ou inc√¥moda.' Em alguns estudos, as observa√ß√µes foram feitas por 'pessoal m√©dico ou param√©dico.'",
            "level_description": "Havia um mecanismo de notifica√ß√£o passiva para eventos graves com instru√ß√µes para relatar mortes e rea√ß√µes s√©rias. No entanto, isso dependia da observa√ß√£o parental e notifica√ß√£o volunt√°ria, em vez de vigil√¢ncia ativa sistem√°tica com avalia√ß√µes cl√≠nicas programadas. A metodologia para identifica√ß√£o de eventos adversos graves fica aqu√©m dos padr√µes de monitoramento ativo."
          },
          "autoimmune_neurological": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "N√£o h√° men√ß√£o de condi√ß√µes autoimunes, encefalite, s√≠ndrome de Guillain-Barr√©, convuls√µes ou outras avalia√ß√µes neurol√≥gicas na documenta√ß√£o dos ensaios cl√≠nicos. Febres altas (at√© 105F) foram documentadas em algumas crian√ßas, mas avalia√ß√£o neurol√≥gica n√£o foi descrita.",
            "level_description": "Os ensaios cl√≠nicos n√£o inclu√≠ram nenhum monitoramento, avalia√ß√£o ou relato espec√≠fico de eventos adversos autoimunes ou neurol√≥gicos. Dado que a vacina MMR foi subsequentemente associada a casos raros de convuls√µes febris, p√∫rpura trombocitop√™nica imune e encefalite, a aus√™ncia de qualquer monitoramento nos ensaios originais representa uma lacuna significativa."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Crian√ßas com leucemia, dist√∫rbios imunol√≥gicos ou recebendo medicamentos imunossupressores foram explicitamente exclu√≠das dos ensaios. Nenhuma an√°lise separada ou inclus√£o de beb√™s prematuros, crian√ßas com alergias, doen√ßas cr√¥nicas ou outras popula√ß√µes vulner√°veis est√° documentada.",
            "level_description": "Subgrupos vulner√°veis foram sistematicamente exclu√≠dos dos ensaios cl√≠nicos em vez de estudados. N√£o h√° dados de seguran√ßa dos ensaios pr√©-licenciamento para crian√ßas imunocomprometidas, beb√™s prematuros ou crian√ßas com condi√ß√µes cr√¥nicas de sa√∫de que posteriormente receberiam esta vacina no uso do mundo real."
          },
          "statistical_analysis": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "Um memorando descreve 'An√°lise de vari√¢ncia foi conduzida nos t√≠tulos p√≥s' comparando grupos de vacina de rub√©ola. Taxas de soroconvers√£o e t√≠tulos m√©dios geom√©tricos s√£o relatados com porcentagens. Um memorando afirma 'N√£o existe diferen√ßa significativa entre os tr√™s grupos.'",
            "level_description": "An√°lise estat√≠stica b√°sica (ANOVA, taxas de soroconvers√£o, t√≠tulos m√©dios geom√©tricos) foi realizada para desfechos de imunogenicidade. No entanto, nenhum c√°lculo de poder para detec√ß√£o de seguran√ßa est√° documentado, e os pequenos tamanhos de amostra impedem an√°lise estat√≠stica significativa de eventos adversos. Os estudos foram dimensionados para efic√°cia, n√£o para seguran√ßa."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "what_document_states": "O documento foi liberado atrav√©s de uma solicita√ß√£o FOIA datada de agosto de 2019, mais de 40 anos ap√≥s o licenciamento de 1978. A carta de apresenta√ß√£o observa que 'partes de p√°ginas' foram retidas sob a Isen√ß√£o 4 (segredos comerciais) e Isen√ß√£o 6 (privacidade pessoal). Registros detalhados de antecedentes foram declarados como estando 'arquivados na Pesquisa de V√≠rus e Biologia Celular, Instituto Merck.'",
            "level_description": "Este documento foi obtido apenas atrav√©s de solicita√ß√£o FOIA d√©cadas ap√≥s a aprova√ß√£o, com partes redigidas. Dados individuais de pacientes n√£o est√£o dispon√≠veis publicamente. Nenhum Comit√™ Independente de Monitoramento de Seguran√ßa de Dados √© mencionado. A libera√ß√£o tardia e parcial dos dados dos ensaios cl√≠nicos limita a verifica√ß√£o independente dos achados de seguran√ßa."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "O documento cobre apenas ensaios cl√≠nicos pr√©-licenciamento. Nenhum plano de vigil√¢ncia p√≥s-comercializa√ß√£o, sistema de notifica√ß√£o passiva (como o VAERS, que n√£o existia at√© 1990), ou monitoramento cont√≠nuo de seguran√ßa √© descrito.",
            "level_description": "O documento de licenciamento de 1978 n√£o cont√©m disposi√ß√µes de vigil√¢ncia p√≥s-comercializa√ß√£o. O VAERS n√£o foi estabelecido at√© 1990. A aus√™ncia completa de monitoramento de seguran√ßa p√≥s-comercializa√ß√£o nos documentos de aprova√ß√£o originais significa que a avalia√ß√£o de seguran√ßa dependeu inteiramente dos ensaios pr√©-licenciamento limitados."
          },
          "conflict_of_interest": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "what_document_states": "Todos os estudos cl√≠nicos foram conduzidos sob a responsabilidade geral do Dr. Maurice R. Hilleman, Vice-Presidente de Pesquisa em V√≠rus e Biologia Celular, Instituto Merck de Pesquisa Terap√™utica. As vacinas foram preparadas pela Merck Sharp and Dohme Biologics Manufacturing. Testes sorol√≥gicos foram realizados em laborat√≥rios da Merck. Os investigadores cl√≠nicos reportavam diretamente √† Merck.",
            "level_description": "Os ensaios foram inteiramente projetados, gerenciados e analisados pelo fabricante da vacina. O investigador principal era Vice-Presidente da Merck. Nenhuma supervis√£o independente, monitoramento externo ou divulga√ß√£o de relacionamentos financeiros est√° documentada. Isso representa um conflito de interesse fundamental sem medidas de mitiga√ß√£o descritas."
          },
          "all_cause_mortality": {
            "rating": "absent",
            "emoji": "‚ùì",
            "what_document_states": "Os protocolos mencionam que 'morte por qualquer causa durante a investiga√ß√£o, relacionada ou n√£o ao material de teste, deve ser relatada imediatamente.' No entanto, nenhum dado de mortalidade, relato de morte ou an√°lise sistem√°tica de mortalidade aparece na documenta√ß√£o dos resultados.",
            "level_description": "Embora o protocolo exigisse notifica√ß√£o de mortes, nenhum dado de mortalidade √© apresentado nos resultados dos ensaios cl√≠nicos. N√£o h√° compara√ß√£o sistem√°tica de mortalidade por todas as causas entre os grupos de vacina ou documenta√ß√£o sobre se ocorreram mortes durante o per√≠odo de acompanhamento de 42 dias."
          }
        },
        "overall": {
          "rating": "insufficient",
          "emoji": "üî¥",
          "summary": "Os estudos de licenciamento da M-M-R II de 1978 demonstram limita√ß√µes metodol√≥gicas significativas por qualquer padr√£o de avalia√ß√£o de seguran√ßa. Os ensaios inclu√≠ram apenas aproximadamente 834 crian√ßas recebendo a vacina combinada, muito abaixo do m√≠nimo de 3.000 por faixa et√°ria necess√°rio para detectar eventos adversos raros. O acompanhamento foi limitado a 42 dias, impossibilitando a detec√ß√£o de rea√ß√µes autoimunes ou neurol√≥gicas tardias. Nenhum controle placebo verdadeiro foi usado - em vez disso, compararam-se diferentes formula√ß√µes de vacinas. Os estudos n√£o tinham duplo-cego, com a maioria parecendo ser aberta. Os ensaios exclu√≠ram popula√ß√µes vulner√°veis (imunocomprometidos, beb√™s prematuros) que posteriormente receberiam a vacina. Nenhuma avalia√ß√£o de desfechos autoimunes ou neurol√≥gicos foi realizada, apesar de estes terem sido posteriormente identificados como eventos adversos raros. Todo o programa de pesquisa foi conduzido pelo fabricante sem supervis√£o independente, representando um conflito de interesse n√£o mitigado. Embora os estudos possam ter sido padr√£o para sua √©poca, eles ficam dramaticamente aqu√©m dos requisitos modernos de avalia√ß√£o de seguran√ßa de vacinas pedi√°tricas e deixam incerteza substancial sobre o verdadeiro perfil de eventos adversos da M-M-R II."
        }
      },
      "safety_en": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "en",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "The document reports a total of 834 children vaccinated across multiple studies (442, 443, 459, 467, 473, 484, 511, 513). While this represents a substantial effort for the era, it is far below the modern standard of >3,000 children per age group needed to detect rare adverse events (1 in 1,000 or 1 in 10,000). The sample size of 834 can only reliably detect events occurring at a frequency of approximately 1 in 100-300. Children ranged from 10 months to 15 years of age (mean ages typically 1.4-4.3 years), with no breakdown by age group sufficient for subgroup safety analysis."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "Follow-up was limited to 6 weeks (42 days) post-vaccination across all studies. The protocol explicitly states: 'Each child will be followed clinically for 42 days following vaccination.' Parents were asked to 'take daily temperatures and record all symptoms which occur during the following six weeks.' This timeframe is grossly inadequate to detect autoimmune conditions, neurological sequelae, or developmental effects that may manifest months or years after vaccination. The ideal minimum is 12 months, with 2-3+ years preferred for long-term safety assessment."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Study 459 included a planned placebo group of 50 children, comparing reactions in children receiving M-M-R vaccines vs. individual component vaccines vs. placebo. However, most studies (442, 443, 467, 473, 511, 513) compared different vaccine formulations (HPV-77 vs RA 27/3 rubella strains) rather than using a true saline placebo control. The comparison was primarily between active vaccines, not vaccine vs. no vaccine. The placebo group in Study 459 was limited to 50 children, which is statistically underpowered for safety signal detection."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "Surveillance methodology varied by study. In studies by Drs. Weibel, Lerman, Gershon, and McCollum, 'observations were recorded daily by the mother' using parent-completed reaction cards and thermometers. Parents were asked to contact physicians for 'significant or bothersome reactions.' In Dr. Villarejos' studies (Nicaragua/Costa Rica), observations were made by 'medical or paramedical personnel' with physicians notified of 'significant illness.' The protocol required reporting of 'any serious or alarming reaction, including death due to any cause' to Merck. However, there is no evidence of systematic medical examinations, proactive outreach, medical record review, or hospitalization/death investigation with formal causality analysis."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "The document contains no evidence of systematic neurological or developmental monitoring. The word 'neurology' appears only as a department name at University of Nebraska. No scheduled developmental assessments, neurological examinations, or surveillance for conditions such as seizures, encephalitis, Guillain-Barre syndrome, or developmental regression are documented. Clinical complaints tracked were limited to fever, rash, irritability, malaise, upper respiratory illness, otitis, gastrointestinal symptoms, and arthralgia. There is no mention of neurological examination protocols or developmental milestone tracking."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "The document explicitly EXCLUDES vulnerable populations rather than including them. The protocols state that children 'with leukemia or other immunologic disorders and persons receiving immunosuppressive drugs should not be vaccinated.' There is no documentation of intentional inclusion of premature infants, immunocompromised children, or children with chronic conditions. No separate safety analysis for any special population subgroup is presented. The study population consisted entirely of healthy children from the 'open population' without documented special conditions."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "The document provides summary tables of antibody responses (seroconversion rates, geometric mean titers) and clinical complaints aggregated by vaccine group and time period. Individual case-level serological data is presented in some tables. Temperature and symptom data are presented as percentages. However, complete individual patient records, raw adverse event data, and case narratives are not included in this FOIA release. The document notes that 'detailed background records are on file in Virus and Cell Biology Research, Merck Institute' and 'are available for review at any time,' but these were not part of the submission. Some portions were withheld under FOIA Exemption 4 (trade secrets) and Exemption 6 (privacy)."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "This is a pre-licensure clinical trial document from 1978. There is no mention of post-marketing surveillance plans, pharmacovigilance systems, VAERS (which was not established until 1990), or ongoing safety monitoring after licensure. The document contains no discussion of how safety would be monitored once the vaccine was in widespread use, no mention of periodic safety reviews, and no reference to mechanisms for detecting rare adverse events that might only appear with millions of doses administered."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "This 1978 FDA FOIA document provides limited safety evidence for M-M-R II vaccine licensure. While the clinical trials demonstrated immunogenicity with seroconversion rates of 95-99% across components, the safety evaluation has significant limitations: only 834 children were studied (insufficient to detect rare events), follow-up was limited to 42 days (inadequate for detecting delayed autoimmune or neurological effects), most studies lacked true placebo controls (comparing vaccine formulations instead), there was no systematic neurological monitoring, vulnerable populations were explicitly excluded, and no post-marketing surveillance was planned. The passive surveillance methodology relied heavily on parent-completed daily cards documenting temperature and symptoms, with no protocol for medical record review or structured causality assessment. The document shows the vaccine produced expected reactions (fever, rash, irritability) at rates considered acceptable for the era, but cannot provide confidence regarding rare serious adverse events or long-term safety in children."
        }
      },
      "safety_pt": {
        "vaccine_id": "mmr_mmrii",
        "analysis_type": "safety",
        "language": "pt",
        "criteria": {
          "pediatric_sample_size": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O documento relata um total de 834 crian√ßas vacinadas em m√∫ltiplos estudos (442, 443, 459, 467, 473, 484, 511, 513). Embora isso represente um esfor√ßo substancial para a √©poca, est√° muito abaixo do padr√£o moderno de >3.000 crian√ßas por faixa et√°ria necess√°rio para detectar eventos adversos raros (1 em 1.000 ou 1 em 10.000). O tamanho amostral de 834 pode detectar de forma confi√°vel apenas eventos que ocorrem com frequ√™ncia aproximada de 1 em 100-300. As crian√ßas tinham entre 10 meses e 15 anos de idade (idades m√©dias tipicamente de 1,4-4,3 anos), sem divis√£o por faixa et√°ria suficiente para an√°lise de seguran√ßa por subgrupo."
          },
          "follow_up_duration": {
            "rating": "insufficient",
            "emoji": "üî¥",
            "explanation": "O acompanhamento foi limitado a 6 semanas (42 dias) p√≥s-vacina√ß√£o em todos os estudos. O protocolo declara explicitamente: 'Cada crian√ßa ser√° acompanhada clinicamente por 42 dias ap√≥s a vacina√ß√£o.' Os pais foram orientados a 'medir a temperatura diariamente e registrar todos os sintomas que ocorrerem durante as seis semanas seguintes.' Este per√≠odo √© grosseiramente inadequado para detectar condi√ß√µes autoimunes, sequelas neurol√≥gicas ou efeitos no desenvolvimento que podem se manifestar meses ou anos ap√≥s a vacina√ß√£o. O m√≠nimo ideal √© de 12 meses, sendo prefer√≠vel 2-3+ anos para avalia√ß√£o de seguran√ßa a longo prazo."
          },
          "comparison_group": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O Estudo 459 incluiu um grupo placebo planejado de 50 crian√ßas, comparando rea√ß√µes em crian√ßas recebendo vacinas M-M-R vs. vacinas de componentes individuais vs. placebo. No entanto, a maioria dos estudos (442, 443, 467, 473, 511, 513) comparou diferentes formula√ß√µes de vacina (cepas de rub√©ola HPV-77 vs RA 27/3) em vez de usar um controle placebo de solu√ß√£o salina verdadeiro. A compara√ß√£o foi principalmente entre vacinas ativas, n√£o vacina vs. nenhuma vacina. O grupo placebo no Estudo 459 foi limitado a 50 crian√ßas, o que √© estatisticamente insuficiente para detec√ß√£o de sinais de seguran√ßa."
          },
          "active_surveillance": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "A metodologia de vigil√¢ncia variou por estudo. Nos estudos dos Drs. Weibel, Lerman, Gershon e McCollum, 'as observa√ß√µes eram registradas diariamente pela m√£e' usando cart√µes de rea√ß√£o preenchidos pelos pais e term√¥metros. Os pais foram orientados a contatar os m√©dicos para 'rea√ß√µes significativas ou inc√¥modas.' Nos estudos do Dr. Villarejos (Nicar√°gua/Costa Rica), as observa√ß√µes eram feitas por 'pessoal m√©dico ou param√©dico' com m√©dicos notificados de 'doen√ßas significativas.' O protocolo exigia relato de 'qualquer rea√ß√£o s√©ria ou alarmante, incluindo morte por qualquer causa' √† Merck. No entanto, n√£o h√° evid√™ncia de exames m√©dicos sistem√°ticos, contato proativo, revis√£o de prontu√°rios m√©dicos ou investiga√ß√£o de hospitaliza√ß√£o/morte com an√°lise formal de causalidade."
          },
          "neurological_monitoring": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "O documento n√£o cont√©m evid√™ncia de monitoramento neurol√≥gico ou do desenvolvimento sistem√°tico. A palavra 'neurologia' aparece apenas como nome de departamento na Universidade de Nebraska. N√£o h√° avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos ou vigil√¢ncia para condi√ß√µes como convuls√µes, encefalite, s√≠ndrome de Guillain-Barr√© ou regress√£o do desenvolvimento documentados. As queixas cl√≠nicas rastreadas foram limitadas a febre, erup√ß√£o cut√¢nea, irritabilidade, mal-estar, doen√ßa respirat√≥ria alta, otite, sintomas gastrointestinais e artralgia. N√£o h√° men√ß√£o de protocolos de exame neurol√≥gico ou acompanhamento de marcos do desenvolvimento."
          },
          "vulnerable_subgroups": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "O documento EXCLUI explicitamente popula√ß√µes vulner√°veis em vez de inclu√≠-las. Os protocolos afirmam que crian√ßas 'com leucemia ou outros dist√∫rbios imunol√≥gicos e pessoas recebendo drogas imunossupressoras n√£o devem ser vacinadas.' N√£o h√° documenta√ß√£o de inclus√£o intencional de beb√™s prematuros, crian√ßas imunocomprometidas ou crian√ßas com condi√ß√µes cr√¥nicas. Nenhuma an√°lise de seguran√ßa separada para qualquer subgrupo de popula√ß√£o especial √© apresentada. A popula√ß√£o do estudo consistiu inteiramente de crian√ßas saud√°veis da 'popula√ß√£o aberta' sem condi√ß√µes especiais documentadas."
          },
          "data_transparency": {
            "rating": "partial",
            "emoji": "‚ö†Ô∏è",
            "explanation": "O documento fornece tabelas resumidas de respostas de anticorpos (taxas de soroconvers√£o, t√≠tulos m√©dios geom√©tricos) e queixas cl√≠nicas agregadas por grupo de vacina e per√≠odo de tempo. Dados sorol√≥gicos individuais de n√≠vel de caso s√£o apresentados em algumas tabelas. Dados de temperatura e sintomas s√£o apresentados como porcentagens. No entanto, registros individuais completos de pacientes, dados brutos de eventos adversos e narrativas de casos n√£o est√£o inclu√≠dos nesta libera√ß√£o FOIA. O documento observa que 'registros detalhados de base est√£o arquivados na Pesquisa de V√≠rus e Biologia Celular, Instituto Merck' e 'est√£o dispon√≠veis para revis√£o a qualquer momento,' mas estes n√£o faziam parte da submiss√£o. Algumas partes foram retidas sob a Isen√ß√£o 4 da FOIA (segredos comerciais) e Isen√ß√£o 6 (privacidade)."
          },
          "post_marketing_surveillance": {
            "rating": "absent",
            "emoji": "‚ùì",
            "explanation": "Este √© um documento de ensaio cl√≠nico pr√©-licenciamento de 1978. N√£o h√° men√ß√£o de planos de vigil√¢ncia p√≥s-comercializa√ß√£o, sistemas de farmacovigil√¢ncia, VAERS (que s√≥ foi estabelecido em 1990) ou monitoramento de seguran√ßa cont√≠nuo ap√≥s o licenciamento. O documento n√£o cont√©m discuss√£o sobre como a seguran√ßa seria monitorada uma vez que a vacina estivesse em uso generalizado, nenhuma men√ß√£o de revis√µes peri√≥dicas de seguran√ßa e nenhuma refer√™ncia a mecanismos para detectar eventos adversos raros que podem aparecer apenas com milh√µes de doses administradas."
          }
        },
        "overall": {
          "rating": "partial",
          "emoji": "‚ö†Ô∏è",
          "summary": "Este documento FOIA da FDA de 1978 fornece evid√™ncia de seguran√ßa limitada para o licenciamento da vacina M-M-R II. Embora os ensaios cl√≠nicos tenham demonstrado imunogenicidade com taxas de soroconvers√£o de 95-99% em todos os componentes, a avalia√ß√£o de seguran√ßa tem limita√ß√µes significativas: apenas 834 crian√ßas foram estudadas (insuficiente para detectar eventos raros), o acompanhamento foi limitado a 42 dias (inadequado para detectar efeitos autoimunes ou neurol√≥gicos tardios), a maioria dos estudos n√£o tinha controles placebo verdadeiros (comparando formula√ß√µes de vacinas em vez disso), n√£o houve monitoramento neurol√≥gico sistem√°tico, popula√ß√µes vulner√°veis foram explicitamente exclu√≠das e nenhuma vigil√¢ncia p√≥s-comercializa√ß√£o foi planejada. A metodologia de vigil√¢ncia passiva dependia fortemente de cart√µes di√°rios preenchidos pelos pais documentando temperatura e sintomas, sem protocolo para revis√£o de prontu√°rios m√©dicos ou avalia√ß√£o estruturada de causalidade. O documento mostra que a vacina produziu rea√ß√µes esperadas (febre, erup√ß√£o cut√¢nea, irritabilidade) em taxas consideradas aceit√°veis para a √©poca, mas n√£o pode fornecer confian√ßa em rela√ß√£o a eventos adversos s√©rios raros ou seguran√ßa a longo prazo em crian√ßas."
        }
      }
    }
  ],
  "criteria_trial": {
    "placebo_control": {
      "id": "placebo_control",
      "name": "Placebo control group",
      "name_pt": "Grupo controle com placebo",
      "why_it_matters": "Allows identification of which reactions are caused by the vaccine vs. coincidental events",
      "why_it_matters_pt": "Permite identificar quais rea√ß√µes s√£o causadas pela vacina vs. eventos coincidentes",
      "what_is_ideal": "Inert placebo (saline). Using another vaccine as comparator obscures true adverse event rates",
      "what_is_ideal_pt": "Placebo inerte (solu√ß√£o salina). Usar outra vacina como comparador obscurece as taxas reais de eventos adversos"
    },
    "double_blind": {
      "id": "double_blind",
      "name": "Double-blind study",
      "name_pt": "Estudo duplo-cego",
      "why_it_matters": "Prevents bias in observation and symptom reporting",
      "why_it_matters_pt": "Previne vi√©s na observa√ß√£o e relato de sintomas",
      "what_is_ideal": "Neither participants nor researchers know who received vaccine/placebo",
      "what_is_ideal_pt": "Nem participantes nem pesquisadores sabem quem recebeu vacina/placebo"
    },
    "randomization": {
      "id": "randomization",
      "name": "Randomization",
      "name_pt": "Randomiza√ß√£o",
      "why_it_matters": "Ensures differences in outcomes are due to the vaccine, not pre-existing characteristics",
      "why_it_matters_pt": "Garante que diferen√ßas nos resultados s√£o devido √† vacina, n√£o caracter√≠sticas pr√©-existentes",
      "what_is_ideal": "Documented random allocation with allocation concealment",
      "what_is_ideal_pt": "Aloca√ß√£o aleat√≥ria documentada com oculta√ß√£o da aloca√ß√£o"
    },
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare reactions. Detecting 1:1,000 events requires ~3,000 participants",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar rea√ß√µes raras. Detectar eventos 1:1.000 requer ~3.000 participantes",
      "what_is_ideal": ">3,000 children per age group for adequate safety detection",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio para detec√ß√£o adequada de seguran√ßa"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune/neurological reactions may emerge weeks or months later",
      "why_it_matters_pt": "Rea√ß√µes autoimunes/neurol√≥gicas podem surgir semanas ou meses depois",
      "what_is_ideal": "Minimum 6-12 months; ideal: several years with scheduled assessments",
      "what_is_ideal_pt": "M√≠nimo 6-12 meses; ideal: v√°rios anos com avalia√ß√µes programadas"
    },
    "separate_age_groups": {
      "id": "separate_age_groups",
      "name": "Separate age groups",
      "name_pt": "Grupos et√°rios separados",
      "why_it_matters": "Infants, toddlers, and older children have different immune systems",
      "why_it_matters_pt": "Beb√™s, crian√ßas pequenas e crian√ßas mais velhas t√™m sistemas imunol√≥gicos diferentes",
      "what_is_ideal": "Separate analysis: 0-1 years, 1-5 years, 6-12 years",
      "what_is_ideal_pt": "An√°lise separada: 0-1 ano, 1-5 anos, 6-12 anos"
    },
    "inclusion_exclusion_criteria": {
      "id": "inclusion_exclusion_criteria",
      "name": "Inclusion/exclusion criteria",
      "name_pt": "Crit√©rios de inclus√£o/exclus√£o",
      "why_it_matters": "Allows understanding of who the results apply to",
      "why_it_matters_pt": "Permite entender a quem os resultados se aplicam",
      "what_is_ideal": "Balanced criteria that include representative population",
      "what_is_ideal_pt": "Crit√©rios equilibrados que incluem popula√ß√£o representativa"
    },
    "standardized_adverse_events": {
      "id": "standardized_adverse_events",
      "name": "Standardized definition of adverse events",
      "name_pt": "Defini√ß√£o padronizada de eventos adversos",
      "why_it_matters": "Enables comparison across studies and prevents under/over-reporting",
      "why_it_matters_pt": "Permite compara√ß√£o entre estudos e previne sub/super-notifica√ß√£o",
      "what_is_ideal": "Brighton Collaboration criteria or MedDRA coding",
      "what_is_ideal_pt": "Crit√©rios Brighton Collaboration ou codifica√ß√£o MedDRA"
    },
    "active_monitoring_serious": {
      "id": "active_monitoring_serious",
      "name": "Active monitoring of serious adverse events",
      "name_pt": "Monitoramento ativo de eventos adversos graves",
      "why_it_matters": "Passive/unsolicited reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva/n√£o solicitada subestima muito os eventos graves",
      "what_is_ideal": "Active solicited surveillance for hospitalization, sequelae, deaths",
      "what_is_ideal_pt": "Vigil√¢ncia ativa solicitada para hospitaliza√ß√£o, sequelas, mortes"
    },
    "autoimmune_neurological": {
      "id": "autoimmune_neurological",
      "name": "Assessment of autoimmune/neurological reactions",
      "name_pt": "Avalia√ß√£o de rea√ß√µes autoimunes/neurol√≥gicas",
      "why_it_matters": "Conditions like Guillain-Barr√©, seizures, myocarditis are rare but serious",
      "why_it_matters_pt": "Condi√ß√µes como Guillain-Barr√©, convuls√µes, miocardite s√£o raras mas graves",
      "what_is_ideal": "Specific long-term monitoring with scheduled exams",
      "what_is_ideal_pt": "Monitoramento espec√≠fico de longo prazo com exames programados"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature, immunocompromised children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras, imunocomprometidas podem reagir diferentemente",
      "what_is_ideal": "Intentional inclusion and separate analysis of these groups",
      "what_is_ideal_pt": "Inclus√£o intencional e an√°lise separada desses grupos"
    },
    "statistical_analysis": {
      "id": "statistical_analysis",
      "name": "Robust statistical analysis",
      "name_pt": "An√°lise estat√≠stica robusta",
      "why_it_matters": "Most vaccine trials are powered for efficacy, not safety",
      "why_it_matters_pt": "A maioria dos ensaios de vacinas tem poder para efic√°cia, n√£o seguran√ßa",
      "what_is_ideal": "Study powered for safety outcomes; confidence intervals documented",
      "what_is_ideal_pt": "Estudo com poder para desfechos de seguran√ßa; intervalos de confian√ßa documentados"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Allows independent verification by other researchers",
      "why_it_matters_pt": "Permite verifica√ß√£o independente por outros pesquisadores",
      "what_is_ideal": "Independent DSMB; raw data available; peer-reviewed publication",
      "what_is_ideal_pt": "DSMB independente; dados brutos dispon√≠veis; publica√ß√£o revisada por pares"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "Detects rare reactions that only appear in millions of doses",
      "why_it_matters_pt": "Detecta rea√ß√µes raras que s√≥ aparecem em milh√µes de doses",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    },
    "conflict_of_interest": {
      "id": "conflict_of_interest",
      "name": "Conflict of interest / funding source",
      "name_pt": "Conflito de interesse / fonte de financiamento",
      "why_it_matters": "Industry-funded studies are more likely to report favorable outcomes",
      "why_it_matters_pt": "Estudos financiados pela ind√∫stria tendem a relatar resultados favor√°veis",
      "what_is_ideal": "Independent funding or full disclosure of all financial ties",
      "what_is_ideal_pt": "Financiamento independente ou divulga√ß√£o completa de todos os v√≠nculos financeiros"
    },
    "all_cause_mortality": {
      "id": "all_cause_mortality",
      "name": "All-cause mortality and morbidity",
      "name_pt": "Mortalidade e morbidade por todas as causas",
      "why_it_matters": "Focusing only on vaccine-related outcomes can miss overall harm",
      "why_it_matters_pt": "Focar apenas em resultados relacionados √† vacina pode perder danos gerais",
      "what_is_ideal": "Report total deaths and hospitalizations in all groups",
      "what_is_ideal_pt": "Relatar total de mortes e hospitaliza√ß√µes em todos os grupos"
    }
  },
  "criteria_safety": {
    "pediatric_sample_size": {
      "id": "pediatric_sample_size",
      "name": "Pediatric sample size",
      "name_pt": "Tamanho da amostra pedi√°trica",
      "why_it_matters": "Small samples cannot detect rare events (1 in 1,000, 1 in 10,000)",
      "why_it_matters_pt": "Amostras pequenas n√£o podem detectar eventos raros (1 em 1.000, 1 em 10.000)",
      "what_is_ideal": ">3,000 children per age group",
      "what_is_ideal_pt": ">3.000 crian√ßas por grupo et√°rio"
    },
    "follow_up_duration": {
      "id": "follow_up_duration",
      "name": "Follow-up duration",
      "name_pt": "Dura√ß√£o do acompanhamento",
      "why_it_matters": "Autoimmune and neurological problems may take months or years to appear",
      "why_it_matters_pt": "Problemas autoimunes e neurol√≥gicos podem levar meses ou anos para aparecer",
      "what_is_ideal": "Minimum 12 months; 2-3+ years to assess long-term effects",
      "what_is_ideal_pt": "M√≠nimo 12 meses; 2-3+ anos para avaliar efeitos de longo prazo"
    },
    "comparison_group": {
      "id": "comparison_group",
      "name": "Comparison group",
      "name_pt": "Grupo de compara√ß√£o",
      "why_it_matters": "Need a group that did not receive the vaccine for comparison",
      "why_it_matters_pt": "Precisa de um grupo que n√£o recebeu a vacina para compara√ß√£o",
      "what_is_ideal": "True placebo (saline solution), with randomization and double-blind",
      "what_is_ideal_pt": "Placebo verdadeiro (solu√ß√£o salina), com randomiza√ß√£o e duplo-cego"
    },
    "active_surveillance": {
      "id": "active_surveillance",
      "name": "Active surveillance for serious events",
      "name_pt": "Vigil√¢ncia ativa para eventos graves",
      "why_it_matters": "Passive reporting vastly underestimates serious events",
      "why_it_matters_pt": "Notifica√ß√£o passiva subestima muito eventos graves",
      "what_is_ideal": "Regular contact with families, review of medical records, causality analysis",
      "what_is_ideal_pt": "Contato regular com fam√≠lias, revis√£o de prontu√°rios, an√°lise de causalidade"
    },
    "neurological_monitoring": {
      "id": "neurological_monitoring",
      "name": "Neurological/developmental monitoring",
      "name_pt": "Monitoramento neurol√≥gico/desenvolvimento",
      "why_it_matters": "Check if children developed normally months and years later",
      "why_it_matters_pt": "Verificar se as crian√ßas se desenvolveram normalmente meses e anos depois",
      "what_is_ideal": "Scheduled developmental assessments, follow-up neurological exams",
      "what_is_ideal_pt": "Avalia√ß√µes de desenvolvimento programadas, exames neurol√≥gicos de acompanhamento"
    },
    "vulnerable_subgroups": {
      "id": "vulnerable_subgroups",
      "name": "Vulnerable subgroups",
      "name_pt": "Subgrupos vulner√°veis",
      "why_it_matters": "Premature and immunosuppressed children may react differently",
      "why_it_matters_pt": "Crian√ßas prematuras e imunossuprimidas podem reagir diferentemente",
      "what_is_ideal": "These groups intentionally included with results presented separately",
      "what_is_ideal_pt": "Esses grupos intencionalmente inclu√≠dos com resultados apresentados separadamente"
    },
    "data_transparency": {
      "id": "data_transparency",
      "name": "Data transparency",
      "name_pt": "Transpar√™ncia dos dados",
      "why_it_matters": "Is it possible to verify the complete study data?",
      "why_it_matters_pt": "√â poss√≠vel verificar os dados completos do estudo?",
      "what_is_ideal": "Peer-reviewed publication with complete adverse event data",
      "what_is_ideal_pt": "Publica√ß√£o revisada por pares com dados completos de eventos adversos"
    },
    "post_marketing_surveillance": {
      "id": "post_marketing_surveillance",
      "name": "Post-marketing surveillance",
      "name_pt": "Vigil√¢ncia p√≥s-comercializa√ß√£o",
      "why_it_matters": "What was discovered after millions of children received it?",
      "why_it_matters_pt": "O que foi descoberto ap√≥s milh√µes de crian√ßas receberem?",
      "what_is_ideal": "Active pharmacovigilance system with periodic public reports",
      "what_is_ideal_pt": "Sistema ativo de farmacovigil√¢ncia com relat√≥rios p√∫blicos peri√≥dicos"
    }
  },
  "metadata": {
    "generated_at": "2026-01-11T03:40:17.164330Z",
    "vaccines_count": 3,
    "verification_status": "all_verified"
  }
}